id,conversation_id,created_at,date,time,timezone,user_id,username,name,place,tweet,language,mentions,urls,photos,replies_count,retweets_count,likes_count,hashtags,cashtags,link,retweet,quote_url,video,thumbnail,near,geo,source,user_rt_id,user_rt,retweet_id,reply_to,retweet_date,translate,trans_src,trans_dest
1212028035848949760,1212028035848949760,2019-12-31 20:39:36 IST,2019-12-31,20:39:36,+0530,61342056,optionshawk,Joe Kunkle,,"Gilead $GILD IV rising after 10am as February $70 calls heat up with 10,000 trading $0.76 to $0.88",en,[],[],[],0,4,12,[],['gild'],https://twitter.com/OptionsHawk/status/1212028035848949760,False,,0,,,,,,,,[],,,,
1210991872765771776,1210989934137487364,2019-12-29 00:02:16 IST,2019-12-29,00:02:16,+0530,4496252499,persimmonti,Persimmon Tree Investments,,"@semodough $GILD  O’Day has his work cut out for him, and I do think that he is the person for the job.  imo, Gilead may be wise to move from the patient partner (e.g. $GLPG $SGMO) to the bold suitor...  Friend-zoned no more, make a splash, the ocean beckons:  $AMRN?  Cash flow for days...",en,[],[],[],1,1,8,[],"['gild', 'glpg', 'sgmo', 'amrn']",https://twitter.com/PersimmonTI/status/1210991872765771776,False,,0,,,,,,,,"[{'screen_name': 'semodough', 'name': 'dough', 'id': '3426014292'}]",,,,
1209480073419595776,1209480073419595776,2019-12-24 19:54:55 IST,2019-12-24,19:54:55,+0530,814893508066680832,tradewithninja,TheTradingNinja[14+30=Lotto King],,$GILD Gilead Sciences Signs Distribution Deal With Japanese Pharmaceutical Firm for Rheumatoid Arthritis Treatment  https://t.co/A0T3DIdnYU,en,[],[],['https://pbs.twimg.com/media/EMjvtlYW4AA_yFb.jpg'],0,0,14,[],['gild'],https://twitter.com/TradeWithNinja/status/1209480073419595776,False,,1,https://pbs.twimg.com/media/EMjvtlYW4AA_yFb.jpg,,,,,,,[],,,,
1205602727499358209,1205602727499358209,2019-12-14 03:07:43 IST,2019-12-14,03:07:43,+0530,950942636818432006,syinvesting,SY Investing,,"$BMY / $JUNO won the patent infringement trial against $GILD / $KITE regarding CAR-T tech.  Gilead owes Bristol-Myers $585M in damages plus a *27.6% running royalty* on Yescarta sales, including an additional $167M from already owed royalties.  The Kite deal continues to bite...",en,[],[],[],7,12,35,[],"['bmy', 'juno', 'gild', 'kite']",https://twitter.com/syinvesting/status/1205602727499358209,False,,0,,,,,,,,[],,,,
1205583993841868800,1205583993841868800,2019-12-14 01:53:17 IST,2019-12-14,01:53:17,+0530,4859660471,_b_i_o_t_e_c_h_,🅱🅸🅾🆃🅴🅲🅷,,this is bad: $GILD Gilead owes $BMY Bristol-Myers $585 million in damages  plus a 27.6% running royalty on sales of CAR-T cell therapy Yescarta,en,[],[],[],4,6,11,[],"['gild', 'bmy']",https://twitter.com/_B_I_O_T_E_C_H_/status/1205583993841868800,False,,0,,,,,,,,[],,,,
1205570609276739584,1205570609276739584,2019-12-14 01:00:06 IST,2019-12-14,01:00:06,+0530,758386485846544384,realwillmeade,Will Meade,,$AMRN Amarin was up almost 5% before the halt $GILD Gilead was down almost 3% before the halt 🤔,en,[],[],[],8,2,34,[],"['amrn', 'gild']",https://twitter.com/realwillmeade/status/1205570609276739584,False,,0,,,,,,,,[],,,,
1205552193732001793,1205552193732001793,2019-12-13 23:46:55 IST,2019-12-13,23:46:55,+0530,234905402,halftimereport,CNBC Halftime Report,,Gilead Sciences downgraded to underperform at Credit Suisse.  The investment committee debates $GILD and the rest of the health care sector in our #CalloftheDay.  https://t.co/lDIrrxIqfh,en,[],[],[],4,2,15,['calloftheday'],['gild'],https://twitter.com/HalftimeReport/status/1205552193732001793,False,,1,https://pbs.twimg.com/media/ELr7U_MWwAAo6Ax.jpg,,,,,,,[],,,,
1204454036809945088,1204454036809945088,2019-12-10 23:03:14 IST,2019-12-10,23:03:14,+0530,758386485846544384,realwillmeade,Will Meade,,Gilead $GILD quietly added Amarin’s $AMRN Vascepa to its trials 🤔,en,[],[],[],6,6,40,[],"['gild', 'amrn']",https://twitter.com/realwillmeade/status/1204454036809945088,False,,0,,,,,,,,[],,,,
1203486405667643392,1203335388602994688,2019-12-08 06:58:13 IST,2019-12-08,06:58:13,+0530,2339881354,maxpowerngs,Max Power,,@osok762 $GILD personnel just put on the $SGMO board and installed as CFO. Gilead sunk their talons into Sangamo and they aren’t going let $PFE get them cheap #biggingwar #AVXSvaluationLand $10B acquisition,en,[],[],[],1,3,8,"['biggingwar', 'avxsvaluationland']","['gild', 'sgmo', 'pfe']",https://twitter.com/MaxPowerNGS/status/1203486405667643392,False,,0,,,,,,,,[],,,,
1199320557885546502,1199320557885546502,2019-11-26 19:04:37 IST,2019-11-26,19:04:37,+0530,4859660471,_b_i_o_t_e_c_h_,🅱🅸🅾🆃🅴🅲🅷,,"next from $GILD !  EX $GILD Gilead's Executive Vice President of Worldwide Commercial Operations, responsible for global commercial activities James R. Meyers joins $SGMO Board of Directors",en,[],[],[],0,7,12,[],"['gild', 'gild', 'sgmo']",https://twitter.com/_B_I_O_T_E_C_H_/status/1199320557885546502,False,,0,,,,,,,,[],,,,
1197395291332329472,1197395291332329472,2019-11-21 11:34:18 IST,2019-11-21,11:34:18,+0530,4859660471,_b_i_o_t_e_c_h_,🅱🅸🅾🆃🅴🅲🅷,,$GILD Gilead CEO Daniel O’Day says company is in an ‘#acquisitive mode’ $SGMO $AGEN $GLPG   https://t.co/F97t3VCXfk,en,[],['https://www.statnews.com/2019/11/20/gilead-ceo-daniel-oday-says-company-is-in-an-acquisitive-mode/'],[],0,10,14,['acquisitive'],"['gild', 'sgmo', 'agen', 'glpg']",https://twitter.com/_B_I_O_T_E_C_H_/status/1197395291332329472,False,,0,,,,,,,,[],,,,
1192439045252616193,1192439045252616193,2019-11-07 19:19:57 IST,2019-11-07,19:19:57,+0530,13171622,pharmalot,pharmalot,,HHS sues Gilead for refusing to reach a licensing deal over patents for HIV prevention pills..  https://t.co/2Zo2DG1V8r #pharma #HIV #AIDS #patents $GILD,en,[],['https://www.statnews.com/pharmalot/2019/11/07/hhs-gilead-hiv-prevention-patents-lawsuit/'],[],0,6,9,"['pharma', 'hiv', 'aids', 'patents']",['gild'],https://twitter.com/pharmalot/status/1192439045252616193,False,,0,,,,,,,,[],,,,
1191134870862548992,1191134870862548992,2019-11-04 04:57:38 IST,2019-11-04,04:57:38,+0530,4496252499,persimmonti,Persimmon Tree Investments,,"$SGMO $GILD  Much ado about Mr. Lee, Sangamo’s new CFO?  The thing is, he comes from Gilead, an upfront $$ and biobucks partner of longstanding...  May put O’Day’s recent remarks on M&amp;A in further context:  https://t.co/Cpkh9ysaDj",en,[],[],['https://pbs.twimg.com/media/EIfC2X9WsAkRDSx.jpg'],0,4,12,[],"['sgmo', 'gild']",https://twitter.com/PersimmonTI/status/1191134870862548992,False,,1,https://pbs.twimg.com/media/EIfC2X9WsAkRDSx.jpg,,,,,,,[],,,,
1190358961414922243,1190358961414922243,2019-11-02 01:34:26 IST,2019-11-02,01:34:26,+0530,19717430,zbiotech,zach,,"*GILEAD TO EXERCISE GALAPAGOS WARRANT, RAISE STAKE TO 25.1%  $GILD $GLPG",en,[],[],[],0,11,21,[],"['gild', 'glpg']",https://twitter.com/zbiotech/status/1190358961414922243,False,,0,,,,,,,,[],,,,
1190237649820368896,1190237649820368896,2019-11-01 17:32:23 IST,2019-11-01,17:32:23,+0530,4859660471,_b_i_o_t_e_c_h_,🅱🅸🅾🆃🅴🅲🅷,,SANGAMO THERAPEUTICS INC - LEE JOINS $SGMO SANGAMO FROM $GILD GILEAD SCIENCES,en,[],[],[],1,5,22,[],"['sgmo', 'gild']",https://twitter.com/_B_I_O_T_E_C_H_/status/1190237649820368896,False,,0,,,,,,,,[],,,,
1187480714134118406,1187480714134118406,2019-10-25 02:57:19 IST,2019-10-25,02:57:19,+0530,16732770,cnbcfastmoney,CNBC's Fast Money,,Gilead getting a bad prognosis from Wall Street as the stock falls after earnings. @megtirrell shares what could be weighing on the stock. $GILD  https://t.co/pvTcls505r,en,"[{'screen_name': 'megtirrell', 'name': 'meg tirrell', 'id': '47678782'}]",[],[],1,6,13,[],['gild'],https://twitter.com/CNBCFastMoney/status/1187480714134118406,False,,1,https://pbs.twimg.com/media/EHrHac9WwAAbMHw.jpg,,,,,,,[],,,,
1187471204291997696,1187471204291997696,2019-10-25 02:19:31 IST,2019-10-25,02:19:31,+0530,588507814,scripmandy,Mandy Jackson,,"$GILD Yescarta thread - Also, earnings release says Gilead is investing in a new viral vector facility in Oceanside (north San Diego County) to boost manufacturing for its T-cell receptor and neoantigen-targeting cell therapies:  https://t.co/EeautiZGhv",en,[],['https://www.businesswire.com/news/home/20191024005897/en/Gilead-Sciences-Announces-Quarter-2019-Financial-Results'],[],0,2,11,[],['gild'],https://twitter.com/ScripMandy/status/1187471204291997696,False,https://twitter.com/bradloncar/status/1187462025196298242,0,,,,,,,,[],,,,
1187465813202231296,1187465288389971968,2019-10-25 01:58:06 IST,2019-10-25,01:58:06,+0530,102094857,adamfeuerstein,Adam Feuerstein,,"@sharkbiotech Maybe it’s just the insanely business week and I’m really tired, but I didn’t even bother to peek at $GILD earnings release. I figured, unless I see on Twitter that Gilead filed for bankruptcy, I can wait to read an analyst report tomorrow.",en,[],[],[],2,0,10,[],['gild'],https://twitter.com/adamfeuerstein/status/1187465813202231296,False,,0,,,,,,,,"[{'screen_name': 'sharkbiotech', 'name': 'Dan Rosenblum', 'id': '255996385'}]",,,,
1187451191908810752,1187451191908810752,2019-10-25 01:00:00 IST,2019-10-25,01:00:00,+0530,857693619406467072,gualestrit,Gualestrit,,"Última media hora de mercado.  No se vayan tras el cierre, llegan los resultados de:  🔥 Amazon $AMZN 🔥 Visa $V 🔥 Intel $INTC 🔥 Gilead $GILD 🔥 Illumina $ILMN 🔥 Capital One $COF  https://t.co/hVS8TI9A2R",es,[],[],['https://pbs.twimg.com/tweet_video_thumb/EHqqZOpX0AUwmTV.jpg'],1,10,47,[],"['amzn', 'v', 'intc', 'gild', 'ilmn', 'cof']",https://twitter.com/gualestrit/status/1187451191908810752,False,,1,https://pbs.twimg.com/tweet_video_thumb/EHqqZOpX0AUwmTV.jpg,,,,,,,[],,,,
1176133084439285764,1176133084439285764,2019-09-23 19:25:53 IST,2019-09-23,19:25:53,+0530,4859660471,_b_i_o_t_e_c_h_,🅱🅸🅾🆃🅴🅲🅷,,RBC $GILD Gilead Partnership Symposium Event Sept. 27 hosting $SGMO $GLPG $AGEN $DRRX  https://t.co/FomZiEAHCa,en,[],[],['https://pbs.twimg.com/media/EFJ2zZpW4AAtLBa.jpg'],1,8,20,[],"['gild', 'sgmo', 'glpg', 'agen', 'drrx']",https://twitter.com/_B_I_O_T_E_C_H_/status/1176133084439285764,False,,1,https://pbs.twimg.com/media/EFJ2zZpW4AAtLBa.jpg,,,,,,,[],,,,
1170018382734716928,1170018382734716928,2019-09-06 22:28:14 IST,2019-09-06,22:28:14,+0530,463177571,mchilberg,Marty Chilberg,,$GILD remains my favorite for #Universal #CAR_T  @kite was better buy than @Juno.  $SGMO is better ex vivo editor than #Crispr #Kymriah supply chain/manufacturing is inferior to #yescarta for autologous.  Market still in love with $ALLO but only because Gilead has been quiet  https://t.co/Me3fCxp967,en,"[{'screen_name': 'kite', 'name': 'kite', 'id': '2300041633'}, {'screen_name': 'juno', 'name': 'juno', 'id': '702173'}]",[],['https://pbs.twimg.com/media/EDy9hI9U0AALOGy.jpg'],3,4,12,"['universal', 'car_t', 'crispr', 'kymriah', 'yescarta']","['gild', 'sgmo', 'allo']",https://twitter.com/mchilberg/status/1170018382734716928,False,,1,https://pbs.twimg.com/media/EDy9hI9U0AALOGy.jpg,,,,,,,[],,,,
1168568821390688257,1168568821390688257,2019-09-02 22:28:12 IST,2019-09-02,22:28:12,+0530,977218325968244738,lama_daila,Lama Daila,,Gilead Sciences Deal With Galapagos NV Should Be A Winner $GLPG $GILD   https://t.co/bf3f7OqTpN,en,[],['https://seekingalpha.com/article/4289185'],[],0,2,16,[],"['glpg', 'gild']",https://twitter.com/Lama_Daila/status/1168568821390688257,False,,0,,,,,,,,[],,,,
1166660730592120833,1166660730592120833,2019-08-28 16:06:08 IST,2019-08-28,16:06:08,+0530,4513090216,lennyvst,Lenny Van Steenhuyse,,I recently provided some color on the Gilead/Galapagos deal to the BioVox team. Here's the full read: $GLPG $GILD,en,[],[],[],0,5,17,[],"['glpg', 'gild']",https://twitter.com/LennyVSt/status/1166660730592120833,False,https://twitter.com/BioVoxBelgium/status/1166648962138411008,0,,,,,,,,[],,,,
1165512656574459904,1165512656574459904,2019-08-25 12:04:06 IST,2019-08-25,12:04:06,+0530,906328017986899968,the_chart_life,"Ian McMillan, CMT",,$GILD Gilead Sciences ...Watching for a break below ~$60 into the Blue circle.  https://t.co/MIJbFbJyEv,en,[],[],['https://pbs.twimg.com/media/ECy7lJTWsAAIoxn.jpg'],0,1,21,[],['gild'],https://twitter.com/the_chart_life/status/1165512656574459904,False,,1,https://pbs.twimg.com/media/ECy7lJTWsAAIoxn.jpg,,,,,,,[],,,,
1156294117401346049,1156294117401346049,2019-07-31 01:32:55 IST,2019-07-31,01:32:55,+0530,430841130,canuck2usa,CtheLightTrading,,Gilead Raises FY19 Product Sales Guidance From $21.3B-$21.8B To $21.6B-$22.1B $GILD  https://t.co/Kul3gUQMP1 @benzinga,en,"[{'screen_name': 'benzinga', 'name': 'benzinga', 'id': '44060322'}]",['https://pro.benzinga.com'],[],0,4,8,[],['gild'],https://twitter.com/canuck2usa/status/1156294117401346049,False,,0,,,,,,,,[],,,,
1156294091333758976,1156294091333758976,2019-07-31 01:32:48 IST,2019-07-31,01:32:48,+0530,430841130,canuck2usa,CtheLightTrading,,"Gilead Sciences Q2 Adj. EPS $1.82 Beats $1.72 Estimate, Sales $5.685B Beat $5.51B Estimate $GILD  https://t.co/Kul3gUQMP1 @benzinga",en,"[{'screen_name': 'benzinga', 'name': 'benzinga', 'id': '44060322'}]",['https://pro.benzinga.com'],[],0,5,11,[],['gild'],https://twitter.com/canuck2usa/status/1156294091333758976,False,,0,,,,,,,,[],,,,
1155974796821164044,1155974796821164044,2019-07-30 04:24:03 IST,2019-07-30,04:24:03,+0530,463177571,mchilberg,Marty Chilberg,,Gotta believe $GILD looked at &gt;50% multiplex efficiency and smiled.  Editing efficiency for $CRSP is about 3 yrs behind for #allo while Gilead is moving ahead to both CD19 and CD20 to reduce CD19 only relapse risk. More novel approach #celltherapy #oncology  https://t.co/neNzV6OUue,en,[],[],"['https://pbs.twimg.com/media/EArY8yFU8AEYhxR.jpg', 'https://pbs.twimg.com/media/EArY8yFU4AAm_Oz.jpg']",2,2,9,"['allo', 'celltherapy', 'oncology']","['gild', 'crsp']",https://twitter.com/mchilberg/status/1155974796821164044,False,,1,https://pbs.twimg.com/media/EArY8yFU8AEYhxR.jpg,,,,,,,[],,,,
1155943635612864512,1155943635612864512,2019-07-30 02:20:13 IST,2019-07-30,02:20:13,+0530,46437396,ebcapital,Todd Campbell,,"#Marijuana Stock Cann('t)Trust, and What's Behind Gilead's Latest Megadeal @themotleyfool #stocks $GILD $GLPG $CTST  https://t.co/PmudlgVKyn",en,"[{'screen_name': 'themotleyfool', 'name': 'the motley fool', 'id': '15568127'}]",['https://www.fool.com/investing/2019/07/29/marijuana-stock-canntrust-and-whats-behind-gileads.aspx'],[],0,2,6,"['marijuana', 'stocks']","['gild', 'glpg', 'ctst']",https://twitter.com/ebcapital/status/1155943635612864512,False,,0,,,,,,,,[],,,,
1150770948343136256,1150770948343136256,2019-07-15 19:45:49 IST,2019-07-15,19:45:49,+0530,2494284157,tradingjustice,Trading Justice,,$GILD Gilead Sciences stock price target cut to $76 from $79 at SVB Leerink. Despite the modest analyst downgrade that is a very nice support zone that has formed on Gilead this year just north of $60. July 30th AMC  https://t.co/pA8NAvg5C2,en,[],[],['https://pbs.twimg.com/media/D_hbsCIU0AIy3l8.jpg'],0,0,6,[],['gild'],https://twitter.com/tradingjustice/status/1150770948343136256,False,,1,https://pbs.twimg.com/media/D_hbsCIU0AIy3l8.jpg,,,,,,,[],,,,
1150733095169122305,1150733095169122305,2019-07-15 17:15:24 IST,2019-07-15,17:15:24,+0530,44438256,matthewherper,Matthew Herper,,"My interview w/ Dan---&gt; With $5 billion Galapagos deal, CEO Daniel O’Day starts putting his stamp on Gilead  https://t.co/UovpYlBMWx $GILD",en,[],['https://www.statnews.com/2019/07/15/with-5-billion-galapagos-deal-ceo-oday-starts-putting-his-stamp-on-gilead/'],[],0,1,8,[],['gild'],https://twitter.com/matthewherper/status/1150733095169122305,False,,0,,,,,,,,[],,,,
1150652885623066625,1150652885623066625,2019-07-15 11:56:40 IST,2019-07-15,11:56:40,+0530,204564525,biostockaddict,BioStockAddict,,This is the best deal Galapagos shareholders coud dream of!   Congrats to Galapagos!Congrats to @OvandeStolpe and team!  Congrats Gilead!   $GLPG $GILD,en,"[{'screen_name': 'ovandestolpe', 'name': 'onno van de stolpe', 'id': '2182215343'}]",[],[],0,1,12,[],"['glpg', 'gild']",https://twitter.com/BioStockAddict/status/1150652885623066625,False,,0,,,,,,,,[],,,,
1150496964078792705,1150496964078792705,2019-07-15 01:37:06 IST,2019-07-15,01:37:06,+0530,166597717,theflynews,The Fly,,"Gilead, Galapagos NV enter into 10-year research, development collaboration $GILD $GLPG  https://t.co/XvAdBR44ga",en,[],['http://dlvr.it/R8PXW1'],[],1,10,3,[],"['gild', 'glpg']",https://twitter.com/theflynews/status/1150496964078792705,False,,0,,,,,,,,[],,,,
1150486263075618817,1150486263075618817,2019-07-15 00:54:34 IST,2019-07-15,00:54:34,+0530,3426014292,semodough,dough,,Wow let this sink in -$GILD to Make $3.95 Billion Upfront Payment and $1.1 Billion Equity Investment – again Gilead to Make $3.95 Billion Upfront Payment and $1.1 Billion Equity Investment –💰💰💰💰,en,[],[],[],2,1,9,[],[],https://twitter.com/semodough/status/1150486263075618817,False,https://twitter.com/MauriceOnTW/status/1150460074613190656,0,,,,,,,,[],,,,
1150473918962122752,1150473918962122752,2019-07-15 00:05:31 IST,2019-07-15,00:05:31,+0530,102754598,johncendpts,John Carroll,,"Looking to resolve lingering doubts, Gilead unleashes a $5B late-stage cash alliance with Galapagos $GILD $GLPG  https://t.co/yuyXvM5peH",en,[],['https://endpts.com/looking-to-resolve-lingering-doubts-gilead-unleashes-a-5b-late-stage-cash-alliance-with-galapagos/'],[],0,16,22,[],"['gild', 'glpg']",https://twitter.com/JohnCendpts/status/1150473918962122752,False,,0,,,,,,,,[],,,,
1150437900053598208,1150437900053598208,2019-07-14 21:42:24 IST,2019-07-14,21:42:24,+0530,3203314919,cararlombardo,Cara Lombardo,,".@WSJ scoop w/ @jonathanrockoff:  Gilead's new CEO won't join the parade of pharma mega-mergers quite yet, instead will spend $5B to deepen ties with Galapagos   https://t.co/pKQLSAS7kW via @WSJ $GILD $GLPG",en,"[{'screen_name': 'wsj', 'name': 'the wall street journal', 'id': '3108351'}, {'screen_name': 'jonathanrockoff', 'name': 'jonathan rockoff', 'id': '18021517'}, {'screen_name': 'wsj', 'name': 'the wall street journal', 'id': '3108351'}]",['https://www.wsj.com/articles/gilead-to-boost-stake-in-belgian-biotech-galapagos-as-part-of-5-1-billion-deal-11563120462?shareToken=st39bc21ab0ee84ca6b34947af2aeef4db'],[],0,18,25,[],"['gild', 'glpg']",https://twitter.com/CaraRLombardo/status/1150437900053598208,False,,0,,,,,,,,[],,,,
1144338754724859909,1144338754724859909,2019-06-28 01:46:34 IST,2019-06-28,01:46:34,+0530,13171622,pharmalot,pharmalot,,Doctors Without Borders accuses Gilead Sciences of breaking a pledge to provide a drug for HIV-related infections.. was it a 'public relations stunt?'  https://t.co/w48hlIn5QZ #pharma #drugprices #HIV #AIDS $GILD $JNJ $PFE $GSKf,en,[],['https://www.statnews.com/pharmalot/2019/06/27/gilead-sciences-hiv-aids-drug-price/'],[],0,10,13,"['pharma', 'drugprices', 'hiv', 'aids']","['gild', 'jnj', 'pfe', 'gskf']",https://twitter.com/pharmalot/status/1144338754724859909,False,,0,,,,,,,,[],,,,
1141443113317126144,1141443113317126144,2019-06-20 02:00:19 IST,2019-06-20,02:00:19,+0530,97334517,allstarcharts,J.C. Parets,,"What's interesting is that with Gilead in a clear downtrend, the ""continuation pattern"" resolved to the upside, instead of the direction of the underlying trend. This battle also took place near former support and resistance levels $GILD  https://t.co/FFVdqJd48r",en,[],[],['https://pbs.twimg.com/media/D9c4LbdVUAAUZtO.png'],0,4,24,[],['gild'],https://twitter.com/allstarcharts/status/1141443113317126144,False,,1,https://pbs.twimg.com/media/D9c4LbdVUAAUZtO.png,,,,,,,[],,,,
1140977928781611009,1140977928781611009,2019-06-18 19:11:51 IST,2019-06-18,19:11:51,+0530,13171622,pharmalot,pharmalot,,"With eyes on Gilead, lawmakers want details on how HHS reviews possible patent infringement..  https://t.co/H9Vvj5BIht #pharma #drugprices #patents $GILD $MYL #HIV #AIDS",en,[],['https://www.statnews.com/pharmalot/2019/06/18/gilead-hiv-aids-patent-hhs-gao/'],[],0,11,15,"['pharma', 'drugprices', 'patents', 'hiv', 'aids']","['gild', 'myl']",https://twitter.com/pharmalot/status/1140977928781611009,False,,0,,,,,,,,[],,,,
1134753213612212224,1134753213612212224,2019-06-01 14:57:03 IST,2019-06-01,14:57:03,+0530,4513090216,lennyvst,Lenny Van Steenhuyse,,"Some Belgian #ASCO19 news: Biocartis to develop assays in support of Kite/Gilead therapies. After checkpoints with BMS, Biocartis now also venturing into the cell therapy field of IO. Cool stuff. $BCART $GILD $BMY",en,[],[],[],0,3,18,['asco19'],"['bcart', 'gild', 'bmy']",https://twitter.com/LennyVSt/status/1134753213612212224,False,https://twitter.com/Biocartis_/status/1134686233723056128,0,,,,,,,,[],,,,
1133476022492336128,1133476022492336128,2019-05-29 02:21:57 IST,2019-05-29,02:21:57,+0530,223207812,truthtracer,truthtracer,,Big pharma missed their $GILD/Pharmasset moment when 11B was a bargain for the 1 trick pony HCV drug sofosbuvir (the focus of Gilead's 2011 acquisition of Pharmasset). That window of opportunity has passed &amp; $ARWR completely understands the broader market for the TrIM ®️ platform,en,[],[],[],2,0,29,[],"['gild', 'arwr']",https://twitter.com/truthtracer/status/1133476022492336128,False,,0,,,,,,,,[],,,,
1130566099890823168,1130566099890823168,2019-05-21 01:38:57 IST,2019-05-21,01:38:57,+0530,4859660471,_b_i_o_t_e_c_h_,🅱🅸🅾🆃🅴🅲🅷,,Credit Suisse: Holding for the Dividend; Waiting for Growth Initiate Coverage of $GILD Gilead with Neutral Rating and $70 TP: allogenic CAR-Ts could blunt sales of this current generation of products + solve manufacturing issues $SGMO $KITE-037 IND for this asset is expected 2H19,en,[],[],[],0,2,9,[],"['gild', 'sgmo', 'kite']",https://twitter.com/_B_I_O_T_E_C_H_/status/1130566099890823168,False,,0,,,,,,,,[],,,,
1129403511945535493,1129403511945535493,2019-05-17 20:39:15 IST,2019-05-17,20:39:15,+0530,245069853,zackfoot,Zachary Prensky,,"Everything you need to know about Congress summed up in 1 exchange between @AOC &amp; $GILD CEO:  ""You're the CEO of Gilead. Is it true that Gilead made $3 billion in profits from Truvada in 2018?"" Ocasio-Cortez asked Gilead CEO Daniel O'Day.  ""$3 billion in revenue,"" he clarified.",en,"[{'screen_name': 'aoc', 'name': 'alexandria ocasio-cortez', 'id': '138203134'}]",[],[],1,4,10,[],['gild'],https://twitter.com/Zackfoot/status/1129403511945535493,False,,0,,,,,,,,[],,,,
1129348935993184257,1129348935993184257,2019-05-17 17:02:23 IST,2019-05-17,17:02:23,+0530,102754598,johncendpts,John Carroll,,"Better than CAR-T? Already prepping for a US launch, MorphoSys posts stellar DLBCL data to field against Novartis, Gilead $MOR $NVS $GILD  https://t.co/CGRcGCSduz",en,[],['https://endpts.com/better-than-car-t-already-prepping-for-a-us-launch-morphosys-preps-stellar-dlbcl-data-to-field-against-novartis-gilead/'],[],0,13,33,[],"['mor', 'nvs', 'gild']",https://twitter.com/JohnCendpts/status/1129348935993184257,False,,0,,,,,,,,[],,,,
1128658820245409792,1128658820245409792,2019-05-15 19:20:06 IST,2019-05-15,19:20:06,+0530,4859660471,_b_i_o_t_e_c_h_,🅱🅸🅾🆃🅴🅲🅷,,"Collaboration Q $GILD allogenic excitement with $SGMO - Sandy  we are very close with them-Collab working #incredibly well. Gilead  making $Kite more independent within company good? Can work either way  ""organization needs Sangamo and works well with Sangamo.""  HT .@mchilberg",en,"[{'screen_name': 'mchilberg', 'name': 'marty chilberg', 'id': '463177571'}]",[],[],0,3,9,['incredibly'],"['gild', 'sgmo', 'kite']",https://twitter.com/_B_I_O_T_E_C_H_/status/1128658820245409792,False,,0,,,,,,,,[],,,,
1126216638641131525,1126216638641131525,2019-05-09 01:35:45 IST,2019-05-09,01:35:45,+0530,4859660471,_b_i_o_t_e_c_h_,🅱🅸🅾🆃🅴🅲🅷,,$SGMO $KITE $GILD just commented on #Allogeneic CAR-T @ Gilead Sciences Inc Annual Shareholders Meeting  https://t.co/iCBIhKAe9i,en,[],[],['https://pbs.twimg.com/media/D6EgCzWWkAAKg7i.jpg'],0,4,8,['allogeneic'],"['sgmo', 'kite', 'gild']",https://twitter.com/_B_I_O_T_E_C_H_/status/1126216638641131525,False,,1,https://pbs.twimg.com/media/D6EgCzWWkAAKg7i.jpg,,,,,,,[],,,,
1126079954511376386,1126079954511376386,2019-05-08 16:32:37 IST,2019-05-08,16:32:37,+0530,3426014292,semodough,dough,,$GILD Gilead Sciences and Goldfinch Bio Announce Strategic Collaboration to Develop Novel Therapies for Kidney Disease  https://t.co/CV0TfwRYXm,en,[],['https://www.gilead.com/news-and-press/press-room/press-releases/2019/5/gilead-sciences-and-goldfinch-bio-announce-strategic-collaboration-to-develop-novel-therapies-for-kidney-disease'],[],0,4,6,[],['gild'],https://twitter.com/semodough/status/1126079954511376386,False,,0,,,,,,,,[],,,,
1126079441409540096,1126079441409540096,2019-05-08 16:30:35 IST,2019-05-08,16:30:35,+0530,102754598,johncendpts,John Carroll,,Gilead wagers $109M — cash — that this biotech can illuminate a drug discovery path pointed straight into the kidney $GILD  https://t.co/O5tgKpdaxa,en,[],['https://endpts.com/gilead-wagers-109m-cash-that-this-biotech-can-illuminate-a-drug-discovery-path-pointed-straight-into-the-kidney/'],[],1,10,28,[],['gild'],https://twitter.com/JohnCendpts/status/1126079441409540096,False,,0,,,,,,,,[],,,,
1124298683913261057,1124298683913261057,2019-05-03 18:34:29 IST,2019-05-03,18:34:29,+0530,597078771,emmarcourt,Emma Court,,How many more O'Day puns from analysts will we have to endure about Gilead's new CEO? Too many I fear. $gild,en,[],[],[],0,0,6,[],['gild'],https://twitter.com/emmarcourt/status/1124298683913261057,False,,0,,,,,,,,[],,,,
1124266372421365760,1124266372421365760,2019-05-03 16:26:05 IST,2019-05-03,16:26:05,+0530,102754598,johncendpts,John Carroll,,"Dan O’Day’s to-do list for Gilead: Recruit a Kite CEO, press the pedal on next-gen cell therapies and start buying stuff $GILD  https://t.co/YIf23c1nEc",en,[],['https://endpts.com/dan-odays-to-do-list-for-gilead-recruit-a-kite-ceo-press-the-pedal-on-next-gen-cell-therapies-and-start-buying-stuff/'],[],0,3,16,[],['gild'],https://twitter.com/JohnCendpts/status/1124266372421365760,False,,0,,,,,,,,[],,,,
1124061668718391296,1124045688134828035,2019-05-03 02:52:40 IST,2019-05-03,02:52:40,+0530,4496252499,persimmonti,Persimmon Tree Investments,,"@bradloncar I understand the point, and $GILD 's bottom line has surely suffered, but...  otoh, what a beautiful chart -- the eradication of a serious indication -- good for you Gilead. Now, get moving with NASH --&gt; $VKTX.",en,[],[],[],1,0,4,[],"['gild', 'vktx']",https://twitter.com/PersimmonTI/status/1124061668718391296,False,,0,,,,,,,,"[{'screen_name': 'bradloncar', 'name': 'Brad Loncar', 'id': '274233761'}]",,,,
1122779626563166208,1122779626563166208,2019-04-29 13:58:17 IST,2019-04-29,13:58:17,+0530,795618706743300096,biotech_junkie,Gene Editing,,"100 pages Piper report out on CAR-T Next Generation Of Cellular Therapy $GILD $KITE  Gilead/Kite: While Autologous Is Improving, Gilead Is Seeking The Next Breakthrough Gilead/Kite’s collaboration with $SGMO Sangamo positions it well to develop #allogeneic products #ASGCT19  https://t.co/gkIVEBbXNz",en,[],[],['https://pbs.twimg.com/media/D5TqFxRWAAA9ea7.jpg'],0,12,33,"['allogeneic', 'asgct19']","['gild', 'kite', 'sgmo']",https://twitter.com/biotech_junkie/status/1122779626563166208,False,,1,https://pbs.twimg.com/media/D5TqFxRWAAA9ea7.jpg,,,,,,,[],,,,
1121383542921895936,1121383542921895936,2019-04-25 17:30:45 IST,2019-04-25,17:30:45,+0530,102527566,biorunup,BioRunUp,,"$GILD #FAIL   Gilead Announces Topline Data From Phase 3 STELLAR-3 Study of Selonsertib in Bridging Fibrosis (F3) Due to Nonalcoholic Steatohepatitis (NASH)   ""did not meet the pre-specified week 48 primary endpoint""",en,[],[],[],0,1,6,['fail'],['gild'],https://twitter.com/BioRunUp/status/1121383542921895936,False,,0,,,,,,,,[],,,,
1116981972620988416,1116981972620988416,2019-04-13 14:00:29 IST,2019-04-13,14:00:29,+0530,401575573,dividendc2,dividendc2,,"Mis TOP 5 - Mejores compañías BIOTECHNOLOGY , largo plazo:  1: Amgen Inc (AMGN)  2: Gilead Sciences Inc (GILD)  3: Celgene Corp (CELG)  4: Illumina Inc (ILMN)  5: Vertex Pharmaceuticals Inc (VRTX)",ca,[],[],[],2,0,14,[],[],https://twitter.com/dividendc2/status/1116981972620988416,False,,0,,,,,,,,[],,,,
1116063537045151744,1116063537045151744,2019-04-11 01:10:57 IST,2019-04-11,01:10:57,+0530,3290364847,statnews,STAT,,"STAT Plus: Gilead Sciences (GILD) is preparing to lay off approximately 20% of its sales force, STAT has learned.  https://t.co/RrRfgquhSy",en,[],['https://buff.ly/2uY9QII'],[],0,8,7,[],[],https://twitter.com/statnews/status/1116063537045151744,False,,0,,,,,,,,[],,,,
1113233426486833153,1113233426486833153,2019-04-03 05:45:06 IST,2019-04-03,05:45:06,+0530,15568127,themotleyfool,The Motley Fool,,"Individual drugs rise and fall, but power players like Gilead Sciences and Teva Pharmaceutical are good bets to bring out new blockbusters to replace the old ones. $GILD $TEVA  https://t.co/gEtAFJdfar",en,[],['https://www.fool.com/investing/2019/04/01/2-incredibly-cheap-pharma-stocks-to-buy-now.aspx'],[],0,3,13,[],"['gild', 'teva']",https://twitter.com/themotleyfool/status/1113233426486833153,False,,0,,,,,,,,[],,,,
1111373386897195008,1111373386897195008,2019-03-29 02:33:58 IST,2019-03-29,02:33:58,+0530,471121755,pnani456,Ani Anirudhan,,$GILD GLPG GILEAD AND GALAPAGOS ANNOUNCE FILGOTINIB MEETS PRIMARY AND KEY SECONDARY ENDPOINTS IN THE PHASE 3 FINCH 1 RHEUMATOID ARTHRITIS STUDY  https://t.co/K7O9dXaIpb,en,[],['https://www.glpg.com/press-releases'],[],0,7,8,[],['gild'],https://twitter.com/pnani456/status/1111373386897195008,False,,0,,,,,,,,[],,,,
1111372854765862913,1111372854765862913,2019-03-29 02:31:51 IST,2019-03-29,02:31:51,+0530,19717430,zbiotech,zach,,Galapagos NV: GILEAD AND GALAPAGOS ANNOUNCE FILGOTINIB MEETS PRIMARY AND KEY SECONDARY ENDPOINTS IN THE PHASE 3  safety also looks fine at first glance  $GLPG $GILD,en,[],[],[],1,5,15,[],"['glpg', 'gild']",https://twitter.com/zbiotech/status/1111372854765862913,False,,0,,,,,,,,[],,,,
1110605598612226053,1110605598612226053,2019-03-26 23:43:03 IST,2019-03-26,23:43:03,+0530,13171622,pharmalot,pharmalot,,Gilead and Louisiana agree to a 'Netflix' subscription model for hepatitis C drugs..  https://t.co/Bx5K7qAy74 #pharma #drugprices #hepatitis $GILD $ABBV $MRK,en,[],['https://www.statnews.com/pharmalot/2019/03/26/gilead-louisiana-netflix-drug-prices-hepatitis/'],[],0,4,6,"['pharma', 'drugprices', 'hepatitis']","['gild', 'abbv', 'mrk']",https://twitter.com/pharmalot/status/1110605598612226053,False,,0,,,,,,,,[],,,,
1107661115981479937,1107661115981479937,2019-03-18 20:42:44 IST,2019-03-18,20:42:44,+0530,901292690167541760,daily_otc,DailyOTC,,"$GILD BMO's Matthew Luchini says Gilead Sciences is a buy citing its HIV franchise that ""should be dominant for at least the next several years."" $QBIO Q Biomed's Set to Transform Multi-Billion Dollar Glaucoma Market  https://t.co/rN1y7JOraE",en,[],['https://www.prnewswire.com/news-releases/q-biomeds-set-to-transform-multi-billion-dollar-glaucoma-market-300810599.html'],[],0,2,2,[],"['gild', 'qbio']",https://twitter.com/daily_otc/status/1107661115981479937,False,,0,,,,,,,,[],,,,
1106659992323657728,1106659992323657728,2019-03-16 02:24:37 IST,2019-03-16,02:24:37,+0530,4859660471,_b_i_o_t_e_c_h_,🅱🅸🅾🆃🅴🅲🅷,,$GILD GILEAD SCIENCES SAYS CEO JOHN MILLIGAN'S 2018 TOTAL COMPENSATION WAS ABOUT $26 MLN VS $15.4 MLN IN 2017  CFO ROBIN WASHINGTON'S 2018 TOTAL COMPENSATION WAS ABOUT $6.3 MLN VS $5.5 MLN IN 2017,en,[],[],[],2,0,4,[],['gild'],https://twitter.com/_B_I_O_T_E_C_H_/status/1106659992323657728,False,,0,,,,,,,,[],,,,
1106299294913564675,1106299294913564675,2019-03-15 02:31:20 IST,2019-03-15,02:31:20,+0530,67066114,dhovekamp42,"`((,(Dieter 'Hovekamp)))",,"Executives On The Move: Biology Leader Exits Gilead, And Promotions At Mitsubishi And Sanofi  cc $AFMD $GILD  https://t.co/Z71zO8HWxl",en,[],['https://scrip.pharmaintelligence.informa.com/articles/2019/03/13/executives-on-the-move-biology-leader-exits-gilead-and-promotions-at-mitsubishi-and-sanofi'],[],0,0,6,[],"['afmd', 'gild']",https://twitter.com/dhovekamp42/status/1106299294913564675,False,,0,,,,,,,,[],,,,
1101829373961871360,1101829373961871360,2019-03-02 18:29:28 IST,2019-03-02,18:29:28,+0530,3426014292,semodough,dough,,BAIRD puts together nice list for $GILD CEO first day - what to buy ???Welcome Daniel O’Day! What will Daniel O’Day do on his first day at Gilead? $MRTX $BPMC $INCY $MDGL $VKTX $ALLO $SGMO $ICPT $GLPG  https://t.co/BBo2QXSQSB,en,[],[],['https://pbs.twimg.com/media/D0p7-PsX0AEfzb9.jpg'],9,9,43,[],"['gild', 'mrtx', 'bpmc', 'incy', 'mdgl', 'vktx', 'allo', 'sgmo', 'icpt', 'glpg']",https://twitter.com/semodough/status/1101829373961871360,False,,1,https://pbs.twimg.com/media/D0p7-PsX0AEfzb9.jpg,,,,,,,[],,,,
1098792497235615745,1098792497235615745,2019-02-22 09:22:00 IST,2019-02-22,09:22:00,+0530,3460109487,endpts,Endpoints News,,Off-the-shelf CAR-T from stem cells? An early look at UCLA tech — licensed by Gilead  https://t.co/TbsxxezwMT $GILD,en,[],['https://endpts.com/off-the-shelf-car-t-from-stem-cells-an-early-look-at-ucla-tech-licensed-by-gilead/'],[],1,3,14,[],['gild'],https://twitter.com/endpts/status/1098792497235615745,False,,0,,,,,,,,[],,,,
1096467096580567040,1096467096580567040,2019-02-15 23:21:41 IST,2019-02-15,23:21:41,+0530,1664138053,davidmoadel,David Moadel,,$GILD #Gilead's Mousetrap  https://t.co/wf6CjswxXx $SLV $GLD $QQQ $DJIA $DIA $SPY #stockmarket #commodities #investing #finance #stocks #gold #silver $FB $TWTR $AAPL $AMZN $TSLA $INTC $AMD $NFLX,en,[],['https://seekingalpha.com/article/4241397-gileads-mousetrap'],[],2,2,7,"['gilead', 'stockmarket', 'commodities', 'investing', 'finance', 'stocks', 'gold', 'silver']","['gild', 'slv', 'gld', 'qqq', 'djia', 'dia', 'spy', 'fb', 'twtr', 'aapl', 'amzn', 'tsla', 'intc', 'amd', 'nflx']",https://twitter.com/davidmoadel/status/1096467096580567040,False,,0,,,,,,,,[],,,,
1095304077070626816,1095304077070626816,2019-02-12 18:20:16 IST,2019-02-12,18:20:16,+0530,849093025884237825,sanctuary_bio,Wilson Cheung,,"$GILD if you actually think about it, Gilead's competence in the anti-virals space is inversely proportional to their competence in basically everything else",en,[],[],[],8,1,20,[],['gild'],https://twitter.com/Sanctuary_Bio/status/1095304077070626816,False,,0,,,,,,,,[],,,,
1095263170816626688,1095263170816626688,2019-02-12 15:37:43 IST,2019-02-12,15:37:43,+0530,2301944706,r4inb0w_,R4inb0w,,🖊️ GENFIT : Article d'ODDO suite à l'échec de la molécule de Gilead dans la #NASH ~ $GNFT #Elafibranor #PBC $GILD $ICPT  https://t.co/Zggnwbk7BI,fr,[],[],['https://pbs.twimg.com/media/DzMnA4xWwAANQrZ.jpg'],1,27,30,"['nash', 'elafibranor', 'pbc']","['gnft', 'gild', 'icpt']",https://twitter.com/R4inb0w_/status/1095263170816626688,False,,1,https://pbs.twimg.com/media/DzMnA4xWwAANQrZ.jpg,,,,,,,[],,,,
1095206300361916416,1095206300361916416,2019-02-12 11:51:44 IST,2019-02-12,11:51:44,+0530,4859660471,_b_i_o_t_e_c_h_,🅱🅸🅾🆃🅴🅲🅷,,"CITI $GILD ""Without NASH, Gilead needs M&amp;A to grow.  Company is looking, keeping future CEO informed.  In speaking with mgmt, the sense of urgency remains, they are actively looking.""",en,[],[],[],6,6,13,[],['gild'],https://twitter.com/_B_I_O_T_E_C_H_/status/1095206300361916416,False,,0,,,,,,,,[],,,,
1095131392411922432,1095131392411922432,2019-02-12 06:54:05 IST,2019-02-12,06:54:05,+0530,3426014292,semodough,dough,,"BAIRD $GILD NASH failure don’t think most Gilead investors saw this as anything more than a flier. However, we don’t see much reason to want to own stock either.-But these results really weren’t even close and continue to believe this whole program is going to be a write-off.",en,[],[],[],0,2,17,[],['gild'],https://twitter.com/semodough/status/1095131392411922432,False,,0,,,,,,,,[],,,,
1093142679188398080,1093142679188398080,2019-02-06 19:11:38 IST,2019-02-06,19:11:38,+0530,466333756,seeitmarket,See It Market,,"$GILD Gilead Sciences Misses Earnings, Cycles Still Bearish -  https://t.co/PQZQBkIV0i  blog by @askslim",en,"[{'screen_name': 'askslim', 'name': 'steve miller', 'id': '19966431'}]",['https://www.seeitmarket.com/gilead-sciences-misses-earnings-gild-stock-turns-bearish-18941/'],[],0,2,7,[],['gild'],https://twitter.com/seeitmarket/status/1093142679188398080,False,,0,,,,,,,,[],,,,
1092751762698596352,1092751762698596352,2019-02-05 17:18:17 IST,2019-02-05,17:18:17,+0530,913260122004086784,kessanman,米国株 決算マン,,ギリアド・サイエンシズ決算 Gilead Sciences (NASDAQ:GILD) Q4 EPS(Non-GAAP) $1.44 予想 -$0.26 売上 $5.8B (-2.5% Y/Y) 予想 +$280M  バイオ製薬大手。株価は時間外で-3.8%  https://t.co/wUraKOf9OQ  https://t.co/zsZebQ13AH,ja,[],['http://investors.gilead.com/news-releases/news-release-details/gilead-sciences-announces-fourth-quarter-and-full-year-2018'],['https://pbs.twimg.com/media/Dyo75m7U0AELeCV.jpg'],0,5,16,[],[],https://twitter.com/KessanMan/status/1092751762698596352,False,,1,https://pbs.twimg.com/media/Dyo75m7U0AELeCV.jpg,,,,,,,[],,,,
1092603585299398656,1092603585299398656,2019-02-05 07:29:28 IST,2019-02-05,07:29:28,+0530,102754598,johncendpts,John Carroll,,Gilead takes an $820M hit after axing a Kite CAR-T. Are billions more going to be incinerated? $GILD -3.25%  https://t.co/jGnKWPXHu7,en,[],['https://endpts.com/gilead-takes-an-820m-hit-after-axing-a-kite-car-t-are-billions-more-going-to-be-incinerated/'],[],1,6,7,[],['gild'],https://twitter.com/JohnCendpts/status/1092603585299398656,False,,0,,,,,,,,[],,,,
1092553470786371585,1092553470786371585,2019-02-05 04:10:20 IST,2019-02-05,04:10:20,+0530,2723696479,dividendhike,dividend hike,,Gilead Sciences hikes dividend by 10.5 percent to $0.63 quarterly. $GILD,en,[],[],[],0,3,8,[],['gild'],https://twitter.com/dividendhike/status/1092553470786371585,False,,0,,,,,,,,[],,,,
1092530678640586754,1092530678640586754,2019-02-05 02:39:46 IST,2019-02-05,02:39:46,+0530,3426014292,semodough,dough,,"$GILD Dec 31, 2018, Gilead had $31.5 billion of cash, During 2018, Gilead generated $8.4 billion in operating cash flow, repaid $6.3 billion of debt, paid cash dividends of $3.0 billion and utilized $2.9 billion on stock repurchases. $GILD its time again -DEAL over repurchase",en,[],[],[],2,3,12,[],"['gild', 'gild']",https://twitter.com/semodough/status/1092530678640586754,False,https://twitter.com/odibro/status/1092528838083514374,0,,,,,,,,[],,,,
1092100934413545472,1092100934413545472,2019-02-03 22:12:07 IST,2019-02-03,22:12:07,+0530,38410914,zappitelli1,Bud Zappitelli,,And GILD earnings tomorrow after close.  Gilead may release news on joint venture ongoing with SGMO @_B_I_O_T_E_C_H_,en,"[{'screen_name': '_b_i_o_t_e_c_h_', 'name': '🅱🅸🅾🆃🅴🅲🅷', 'id': '4859660471'}]",[],[],1,2,16,[],[],https://twitter.com/Zappitelli1/status/1092100934413545472,False,https://twitter.com/pnani456/status/1092090566937063424,0,,,,,,,,[],,,,
1088161814121041920,1088161814121041920,2019-01-24 01:19:28 IST,2019-01-24,01:19:28,+0530,102754598,johncendpts,John Carroll,,Hardest thing in the world is trying to reach Gilead media. The Great and Mighty Oz cannot see you. Will that change under Daniel O'Day? I hope so. This is so old. $GILD,en,[],[],[],1,1,8,[],['gild'],https://twitter.com/JohnCendpts/status/1088161814121041920,False,,0,,,,,,,,[],,,,
1082680686421655553,1082680686421655553,2019-01-08 22:19:25 IST,2019-01-08,22:19:25,+0530,4859660471,_b_i_o_t_e_c_h_,🅱🅸🅾🆃🅴🅲🅷,,$NKTR ENTERED RESEARCH COLLABORATION WITH GILEAD TO EXPLORE COMBINATION OF NKTR-255 WITH ANTIRETROVIRAL THERAPIES IN GILEAD PORTFOLIO        ENTERED INTO RESEARCH COLLABORATION WITH $GILD GILEAD SCIENCES ON DEC 7 - SEC FILING,en,[],[],[],1,1,10,[],"['nktr', 'gild']",https://twitter.com/_B_I_O_T_E_C_H_/status/1082680686421655553,False,,0,,,,,,,,[],,,,
1082333686954106890,1082333686954106890,2019-01-07 23:20:34 IST,2019-01-07,23:20:34,+0530,930174387663273984,stl_biotech,STL Biotech,,"$GILD 's John McHutchison on cell therapy at Gilead: -Yescarta real world data strong -We can manufacture more quickly than our competitors.  -Very active approach in allogenic -Solid tumor programs (neo antigens, viral induced antigens) -Dual antigen targeted programs  #JPM19",en,[],[],[],0,0,7,['jpm19'],['gild'],https://twitter.com/STL_Biotech/status/1082333686954106890,False,,0,,,,,,,,[],,,,
1082067250897534976,1082067250897534976,2019-01-07 05:41:51 IST,2019-01-07,05:41:51,+0530,102754598,johncendpts,John Carroll,,You know that big news story that seemingly comes right on the eve of JP Morgan every year? -- this isn't it: Gilead stuffs another NASH drug discovery program into a growing portfolio $GILD  https://t.co/cGMtRZaZvI,en,[],['https://endpts.com/gilead-stuffs-another-nash-drug-discovery-program-into-a-growing-portfolio/'],[],0,4,5,[],['gild'],https://twitter.com/JohnCendpts/status/1082067250897534976,False,,0,,,,,,,,[],,,,
1072144341408407552,1072144341408407552,2018-12-10 20:31:45 IST,2018-12-10,20:31:45,+0530,295746612,faycortez,Michelle Fay Cortez,,"It will be so interesting to see how Daniel O'Day transforms $GILD, even in the narrow comms world. Roche is known for accessible and fluent executives, and he is one of the most polished. Gilead is one of the most closed shops in the industry. Something's gonna give.",en,[],[],[],0,1,24,[],['gild'],https://twitter.com/FayCortez/status/1072144341408407552,False,,0,,,,,,,,[],,,,
1072119721997283328,1072119721997283328,2018-12-10 18:53:55 IST,2018-12-10,18:53:55,+0530,4859660471,_b_i_o_t_e_c_h_,🅱🅸🅾🆃🅴🅲🅷,,"$GILD Gilead, which has already seen success with an autologous CAR-T  therapy, says it hopes to submit an Investigational New Drug (IND)  request for an #ALLOGENEIC off-the-shelf product in 2019 ; triggering (10x)  $300M milestones to Sangamo $SGMO    https://t.co/uNq1l85jol",en,[],['https://bioprocessintl.com/bioprocess-insider/therapeutic-class/gilead-hopeful-for-allogeneic-ind-next-year/'],[],1,6,18,['allogeneic'],"['gild', 'sgmo']",https://twitter.com/_B_I_O_T_E_C_H_/status/1072119721997283328,False,,0,,,,,,,,[],,,,
1072100438495948800,1072100438495948800,2018-12-10 17:37:17 IST,2018-12-10,17:37:17,+0530,102094857,adamfeuerstein,Adam Feuerstein,,Why Gilead’s new CEO is a solid choice to help the biotech grow again  https://t.co/8EJ6xtmW6W $GILD,en,[],['https://www.statnews.com/2018/12/10/why-gileads-new-ceo-is-a-solid-choice-to-help-the-biotech-grow-again/'],[],0,11,29,[],['gild'],https://twitter.com/adamfeuerstein/status/1072100438495948800,False,,0,,,,,,,,[],,,,
1069279532236988416,1069279532236988416,2018-12-02 22:48:01 IST,2018-12-02,22:48:01,+0530,102094857,adamfeuerstein,Adam Feuerstein,,"Unbowed by critics, Gilead’s cancer chief pushes ahead with growth plans  https://t.co/fczEerY2iU $GILD #ASH18",en,[],['https://www.statnews.com/2018/12/02/gilead-cancer-chief-growth/'],[],1,8,15,['ash18'],['gild'],https://twitter.com/adamfeuerstein/status/1069279532236988416,False,,0,,,,,,,,[],,,,
1069278190458363905,1069278190458363905,2018-12-02 22:42:41 IST,2018-12-02,22:42:41,+0530,4859660471,_b_i_o_t_e_c_h_,🅱🅸🅾🆃🅴🅲🅷,,"$GILD Gilead's trial update showed that for patients who had achieved complete remission 12 months after Yescarta treatment, 93 percent remained in remission after two years. #ASH18",en,[],[],[],0,1,8,['ash18'],['gild'],https://twitter.com/_B_I_O_T_E_C_H_/status/1069278190458363905,False,,0,,,,,,,,[],,,,
1067819890038513664,1067819890038513664,2018-11-28 22:07:55 IST,2018-11-28,22:07:55,+0530,4859660471,_b_i_o_t_e_c_h_,🅱🅸🅾🆃🅴🅲🅷,,$GILD GILD may be using M&amp;A to solve its succession issue and find a NEW CEO “we certainly hope to have somebody announced before the end of the year.” RE $SGMO Sandy Macrae for Gilead CEO  https://t.co/4L4iEmazRj,en,[],[],"['https://pbs.twimg.com/media/DtGoe7oWsAEOlFV.jpg', 'https://pbs.twimg.com/media/DtGof08XgAAVBiw.jpg']",0,3,13,[],"['gild', 'sgmo']",https://twitter.com/_B_I_O_T_E_C_H_/status/1067819890038513664,False,,1,https://pbs.twimg.com/media/DtGoe7oWsAEOlFV.jpg,,,,,,,[],,,,
1055552631471517701,1055552631471517701,2018-10-26 01:42:13 IST,2018-10-26,01:42:13,+0530,951833142133915648,jcm_if,JCM Compounding Knowledge,,Gilead Sciences: Q3 Non-GAAP EPS of $1.84 beats by $0.21; GAAP EPS of $1.60 beats by $0.31. Revenue of $5.6B beats by $230M.    $GILD,en,[],[],[],0,0,5,[],['gild'],https://twitter.com/JCM_IF/status/1055552631471517701,False,,0,,,,,,,,[],,,,
1050616918208479237,1050616918208479237,2018-10-12 10:49:27 IST,2018-10-12,10:49:27,+0530,4859660471,_b_i_o_t_e_c_h_,🅱🅸🅾🆃🅴🅲🅷,,$ALLO is not the only company working on off-the-shelf CAR-T products. $JUNO / $CELG is as well $GILD Gilead signed a partnership deal with #Sangamo Therapeutics to use $SGMO Sangamo’s gene editing tech platform to develop #allogeneic CAR-T products   https://t.co/CXsWPmWzJ5,en,[],['https://www.biospace.com/article/focused-on-off-the-shelf-car-t-allogene-therapeutics-hits-the-nasdaq-at-18-per-share/'],[],0,6,11,"['sangamo', 'allogeneic']","['allo', 'juno', 'celg', 'gild', 'sgmo']",https://twitter.com/_B_I_O_T_E_C_H_/status/1050616918208479237,False,,0,,,,,,,,[],,,,
1048142547929972737,1048142547929972737,2018-10-05 14:57:11 IST,2018-10-05,14:57:11,+0530,35789155,fwpharma,FirstWord Pharma,,NHS England reaches deal to make Gilead's CAR-T cell therapy Yescarta available via Cancer Drugs Fund  https://t.co/tKDSvHPGyh $GILD,en,[],['https://www.firstwordpharma.com/node/1595450'],[],1,8,11,[],['gild'],https://twitter.com/fwpharma/status/1048142547929972737,False,,0,,,,,,,,[],,,,
1047333534363537408,1047333534363537408,2018-10-03 09:22:27 IST,2018-10-03,09:22:27,+0530,826127248952553472,dwyanosaurus,Dwyane,,$GILD load the boat on the rejection. Gilead gon renew its “golden era.”  https://t.co/0cOX409ZWP,en,[],[],['https://pbs.twimg.com/media/DojgS6uUYAEXtqI.jpg'],0,0,5,[],['gild'],https://twitter.com/Dwyanosaurus/status/1047333534363537408,False,,1,https://pbs.twimg.com/media/DojgS6uUYAEXtqI.jpg,,,,,,,[],,,,
1045387049367289856,1045380348752867328,2018-09-28 00:27:49 IST,2018-09-28,00:27:49,+0530,2339881354,maxpowerngs,Max Power,,"@_B_I_O_T_E_C_H_ nice to have the vote of approval from $GILD for $SGMO's Edited Treg plan. Gilead would know better than anyone the potential this has.  Also, we get a clear sign that the knowledge of the acquistion of TxCell was leaked and was a driver for the stock price decline b4 offering",en,[],[],[],1,3,12,[],"['gild', 'sgmo']",https://twitter.com/MaxPowerNGS/status/1045387049367289856,False,,0,,,,,,,,"[{'screen_name': '_B_I_O_T_E_C_H_', 'name': '🅱🅸🅾🆃🅴🅲🅷', 'id': '4859660471'}]",,,,
1039866383360827392,1039866383360827392,2018-09-12 18:50:40 IST,2018-09-12,18:50:40,+0530,102754598,johncendpts,John Carroll,,"Skirting a group of pioneers, Gilead partners with gene-editing upstart Precision Bio in hunt to cure hep B $GILD  https://t.co/vwI8URcTP8",en,[],['https://endpts.com/skirting-a-group-of-pioneers-gilead-partners-with-gene-editing-upstart-precision-bio-in-hunt-to-cure-hep-b/'],[],0,3,12,[],['gild'],https://twitter.com/JohnCendpts/status/1039866383360827392,False,,0,,,,,,,,[],,,,
1039483708854743040,1039483708854743040,2018-09-11 17:30:03 IST,2018-09-11,17:30:03,+0530,102754598,johncendpts,John Carroll,,"Joining the exodus at Gilead, CMO Andrew Cheng makes the switch to biotech CEO — triggering a cross-country move for Akero $GILD  https://t.co/ed2eKBLSBG",en,[],['https://endpts.com/joining-the-exodus-at-gilead-cmo-andrew-cheng-makes-the-switch-to-biotech-ceo-triggering-cross-country-move-to-bay-area/'],[],0,1,5,[],['gild'],https://twitter.com/JohnCendpts/status/1039483708854743040,False,,0,,,,,,,,[],,,,
1035128298462949376,1035128298462949376,2018-08-30 17:03:12 IST,2018-08-30,17:03:12,+0530,102754598,johncendpts,John Carroll,,Amgen vet Laura Hamill takes commercial reins at Gilead amid executive shakeup $AMGN $GILD @AmberTongPW   https://t.co/lfF1XB1BWi,en,"[{'screen_name': 'ambertongpw', 'name': 'amber tong', 'id': '746441781588426752'}]",['https://endpts.com/amgen-vet-laura-hamill-takes-commercial-reins-at-gilead-amid-executive-shakeup/'],[],0,4,5,[],"['amgn', 'gild']",https://twitter.com/JohnCendpts/status/1035128298462949376,False,,0,,,,,,,,[],,,,
1034364021489770496,1034364021489770496,2018-08-28 14:26:14 IST,2018-08-28,14:26:14,+0530,35789155,fwpharma,FirstWord Pharma,,Gilead's CAR-T cell therapy Yescarta gains clearance in Europe for lymphomas  https://t.co/gnLizSX7lc $GILD,en,[],['https://www.firstwordpharma.com/node/1587406'],[],0,7,7,[],['gild'],https://twitter.com/fwpharma/status/1034364021489770496,False,,0,,,,,,,,[],,,,
1034038951563153408,1034038951563153408,2018-08-27 16:54:32 IST,2018-08-27,16:54:32,+0530,102754598,johncendpts,John Carroll,,"Rarely see a partial rollout like this. How bad are $NVS manufacturing problems with CAR-T? Novartis wins a key OK for Kymriah, but continuing manufacturing woes afflict their rollout — rival Gilead breaks into Europe $NVS $GILD  https://t.co/KENtNpnkCT",en,[],['https://endpts.com/novartis-wins-a-key-ok-for-kymriah-but-continuing-manufacturing-woes-afflict-their-rollout-rival-gilead-breaks-into-europe/'],[],3,4,8,[],"['nvs', 'nvs', 'gild']",https://twitter.com/JohnCendpts/status/1034038951563153408,False,,0,,,,,,,,[],,,,
1032245642159120384,1032245642159120384,2018-08-22 18:08:33 IST,2018-08-22,18:08:33,+0530,102754598,johncendpts,John Carroll,,$510M and two lousy PhIIIs later -- Remember momelotinib? Gilead unloads rights to its shelved JAK inhibitor for token $3M payment $GILD $SRRA  https://t.co/CiDPIs8lpW,en,[],['https://endpts.com/remember-momelotinib-gilead-unloads-rights-to-its-shelved-jak-inhibitor-for-token-3m-payment/'],[],3,4,8,[],"['gild', 'srra']",https://twitter.com/JohnCendpts/status/1032245642159120384,False,,0,,,,,,,,[],,,,
1029088244254826496,1029088244254826496,2018-08-14 01:02:11 IST,2018-08-14,01:02:11,+0530,13171622,pharmalot,pharmalot,,Gilead patent for its hepatitis C drug is invalidated by Chinese authorities..  https://t.co/El3BNz1JLg #pharma #hepatitis #drugprices $GILD,en,[],['https://www.statnews.com/pharmalot/2018/08/13/gilead-patents-hepatitis-china/'],[],1,6,7,"['pharma', 'hepatitis', 'drugprices']",['gild'],https://twitter.com/pharmalot/status/1029088244254826496,False,,0,,,,,,,,[],,,,
1024738577924669440,1024738577924669440,2018-08-02 00:58:10 IST,2018-08-02,00:58:10,+0530,913273381440643072,smartmoneyact,Smart Money Action,,"$GILD - over 2,000 January 2019 $77.50 calls bought for around $5.30 today.  Shares of Gilead Sciences recently found some support at the 20-day MA...  https://t.co/3g5MicHjrn",en,[],[],['https://pbs.twimg.com/media/DjiaQpiXgAEgK4k.jpg'],0,3,8,[],['gild'],https://twitter.com/smartmoneyact/status/1024738577924669440,False,,1,https://pbs.twimg.com/media/DjiaQpiXgAEgK4k.jpg,,,,,,,[],,,,
1022236216035614725,1022236216035614725,2018-07-26 03:14:40 IST,2018-07-26,03:14:40,+0530,102094857,adamfeuerstein,Adam Feuerstein,,"Gilead’s golden era ends with the executive departures of ‘The Johns’  https://t.co/nefwzQ5DDP My thoughts on the exits of Milligan and Martin, and the questions for the company they leave behind. $GILD",en,[],['https://www.statnews.com/2018/07/25/gileads-golden-era-ends-with-the-executive-departures-of-the-johns/'],[],2,4,9,[],['gild'],https://twitter.com/adamfeuerstein/status/1022236216035614725,False,,0,,,,,,,,[],,,,
1022227688612921349,1022227688612921349,2018-07-26 02:40:47 IST,2018-07-26,02:40:47,+0530,6810242,bydavidcrow,David Crow,,"""Nothing to see here"" says Mizuho on Gilead CEO exit. He's been CEO for TWO YEARS! $GILD  https://t.co/0GQJLXNW7P",en,[],[],['https://pbs.twimg.com/media/Di-upj-XgAECiNd.jpg'],1,0,5,[],['gild'],https://twitter.com/bydavidcrow/status/1022227688612921349,False,,1,https://pbs.twimg.com/media/Di-upj-XgAECiNd.jpg,,,,,,,[],,,,
1022214253099601920,1022214253099601920,2018-07-26 01:47:24 IST,2018-07-26,01:47:24,+0530,102754598,johncendpts,John Carroll,,Help wanted: New CEO to run Gilead as John Milligan steps down $GILD  https://t.co/AldkWpeIGo,en,[],['https://endpts.com/help-wanted-new-ceo-to-run-gilead-as-john-milligan-steps-down/'],[],2,8,7,[],['gild'],https://twitter.com/JohnCendpts/status/1022214253099601920,False,,0,,,,,,,,[],,,,
1022048126708994049,1022048126708994049,2018-07-25 14:47:16 IST,2018-07-25,14:47:16,+0530,2368733657,bthefirsttoknow,Marketbit.pro,,*GILEAD PATENT EXTENSION FOR TRUVADA MAY BE INVALID: EU COURT $GILD $TEVA,en,[],[],[],0,1,4,[],"['gild', 'teva']",https://twitter.com/bthefirsttoknow/status/1022048126708994049,False,,0,,,,,,,,[],,,,
1021830312828063745,1021830312828063745,2018-07-25 00:21:45 IST,2018-07-25,00:21:45,+0530,13171622,pharmalot,pharmalot,,"Activists want the NIH to sidestep a Gilead patent on an HIV prevention drug.. ""It’s about time pharma feared AIDS activists again,"" said one..  https://t.co/Z94bArdE1p #pharma #drugprices #HIV #patents $GILD",en,[],['https://www.statnews.com/pharmalot/2018/07/24/gilead-hiv-prep-nih-patents/'],[],0,4,5,"['pharma', 'drugprices', 'hiv', 'patents']",['gild'],https://twitter.com/pharmalot/status/1021830312828063745,False,,0,,,,,,,,[],,,,
1016755461922619393,1016755461922619393,2018-07-11 00:16:07 IST,2018-07-11,00:16:07,+0530,884391852119642112,trading_mz,Mz Trading,,"*NOVARTIS, ROCHE, GILEAD CANCEL SOME DRUG PRICE INCREASES $GILD $NVS $IBB",en,[],[],[],0,5,7,[],"['gild', 'nvs', 'ibb']",https://twitter.com/trading_mz/status/1016755461922619393,False,,0,,,,,,,,[],,,,
1005175555711528960,1005175555711528960,2018-06-09 01:21:42 IST,2018-06-09,01:21:42,+0530,4859660471,_b_i_o_t_e_c_h_,🅱🅸🅾🆃🅴🅲🅷,,$GILD says collaboration with $SGMO and the acquisition Cell Design Labs. These  technologies may allow Gilead to be able to control the level of T-cell  response or target the T-cell's activity to a specific tissue or organ  to reduce toxicities.    https://t.co/SRbFCGe6TU,en,[],['https://www.investorvillage.com/smbd.asp?mb=1933&mn=105258&pt=msg&mid=18363363'],[],0,5,13,[],"['gild', 'sgmo']",https://twitter.com/_B_I_O_T_E_C_H_/status/1005175555711528960,False,,0,,,,,,,,[],,,,
1001919775386324993,1001919775386324993,2018-05-31 01:44:23 IST,2018-05-31,01:44:23,+0530,4859660471,_b_i_o_t_e_c_h_,🅱🅸🅾🆃🅴🅲🅷,,PIPER $SGMO Sangamo’s ZFN Technology Can Enable Next-Generation CAR-T Therapy Products The Sangamo Deal Gives Gilead $GILD $KITE A Boost For The Development Of #Allogeneic CAR-T  https://t.co/6vnYTURjNC,en,[],[],"['https://pbs.twimg.com/media/DeeIVvfWAAEmdUf.jpg', 'https://pbs.twimg.com/media/DeeInKSW4AAg847.jpg']",0,12,12,['allogeneic'],"['sgmo', 'gild', 'kite']",https://twitter.com/_B_I_O_T_E_C_H_/status/1001919775386324993,False,,1,https://pbs.twimg.com/media/DeeIVvfWAAEmdUf.jpg,,,,,,,[],,,,
999330151572951040,999330151572951040,2018-05-23 22:14:09 IST,2018-05-23,22:14:09,+0530,4859660471,_b_i_o_t_e_c_h_,🅱🅸🅾🆃🅴🅲🅷,,$GILD Gilead May Have Better Takeover Targets Than $TSRO Tesaro  .. $SGMO  https://t.co/saqE9SuXJl,en,[],['https://scrip.pharmaintelligence.informa.com/articles/2018/05/23/gilead-may-have-better-takeover-targets-than-tesaro'],[],1,1,6,[],"['gild', 'tsro', 'sgmo']",https://twitter.com/_B_I_O_T_E_C_H_/status/999330151572951040,False,,0,,,,,,,,[],,,,
997106407446007808,997105664110493696,2018-05-17 18:57:47 IST,2018-05-17,18:57:47,+0530,57124794,annaedney,Anna Edney,,"Companies that top the naughty list: Celgene, Gilead, Novartis  $CELG $GILD $NOVN",en,[],[],[],2,5,13,[],"['celg', 'gild', 'novn']",https://twitter.com/annaedney/status/997106407446007808,False,,0,,,,,,,,[],,,,
996854191393005568,996854191393005568,2018-05-17 02:15:34 IST,2018-05-17,02:15:34,+0530,1407780158,drmiguelperales,Miguel Perales M.D.,,Gilead to build its EU CAR-T manufacturing facility at Amsterdam airport 🛫  #CARTcell #TcellRx $KITE $GILD  https://t.co/j6lNjmpnYm,en,[],['http://www.fiercepharma.com/pharma/gilead-building-its-eu-car-t-manufacturing-amsterdam'],[],1,15,15,"['cartcell', 'tcellrx']","['kite', 'gild']",https://twitter.com/DrMiguelPerales/status/996854191393005568,False,,0,,,,,,,,[],,,,
996827382853095425,996827382853095425,2018-05-17 00:29:02 IST,2018-05-17,00:29:02,+0530,4859660471,_b_i_o_t_e_c_h_,🅱🅸🅾🆃🅴🅲🅷,,"Transcript from $GILD @ BofAML MAY 16, 2018 / 4:20PM GMT  Analyst asks why Gilead picked $SGMO zinc finger gene editing over CRISPR. heres Gilead´s full answer: #ASGCT18  https://t.co/jtXpVpBxEw",en,[],[],['https://pbs.twimg.com/media/DdVxLJ-WkAYYTab.jpg'],1,10,17,['asgct18'],"['gild', 'sgmo']",https://twitter.com/_B_I_O_T_E_C_H_/status/996827382853095425,False,,1,https://pbs.twimg.com/media/DdVxLJ-WkAYYTab.jpg,,,,,,,[],,,,
996458987452354561,996458987452354561,2018-05-16 00:05:10 IST,2018-05-16,00:05:10,+0530,335254262,lindagailbekker,Linda-Gail Bekker,,Brilliant news! Another barrier to access falls #PrEPForYouth #PrEPworks @DTHF_YC Gilead Sciences (GILD) Says FDA Approves Expanded Indication for Truvada for Reducing the Risk of Acquiring HIV-1 in Adolescents  https://t.co/s3DnXbc17y via @Street_Insider,en,"[{'screen_name': 'dthf_yc', 'name': 'dthf youth centre', 'id': '1021990225'}, {'screen_name': 'street_insider', 'name': 'streetinsider.com', 'id': '84402174'}]",['http://www.streetinsider.com/Corporate+News/Gilead+Sciences+%28GILD%29+Says+FDA+Approves+Expanded+Indication+for+Truvada+for+Reducing+the+Risk+of+Acquiring+HIV-1+in+Adolescents/14194813.html'],[],0,9,10,"['prepforyouth', 'prepworks']",[],https://twitter.com/LindaGailBekker/status/996458987452354561,False,,0,,,,,,,,[],,,,
996385532736409600,996385532736409600,2018-05-15 19:13:17 IST,2018-05-15,19:13:17,+0530,102754598,johncendpts,John Carroll,,"Gilead fortifies its cell therapy status, expanding into three new facilities and teaming with NCI $GILD  https://t.co/sHZ4OFFnvq",en,[],['https://endpts.com/gilead-fortifies-its-cell-therapy-status-expanding-into-three-new-facilities-and-teaming-with-nci/'],[],0,5,12,[],['gild'],https://twitter.com/JohnCendpts/status/996385532736409600,False,,0,,,,,,,,[],,,,
995981734880702464,995981734880702464,2018-05-14 16:28:44 IST,2018-05-14,16:28:44,+0530,3426014292,semodough,dough,,"$GLPG $GILD Gilead/Galapagos’ filgotinib has completed enrollment in the methotrexate naive study FINCH 3. Based on a 24 week primary endpoint, this points to data potentially as early as YE18",en,[],[],[],0,2,16,[],"['glpg', 'gild']",https://twitter.com/semodough/status/995981734880702464,False,,0,,,,,,,,[],,,,
994217623712870400,993939989280026624,2018-05-09 19:38:47 IST,2018-05-09,19:38:47,+0530,4859660471,_b_i_o_t_e_c_h_,🅱🅸🅾🆃🅴🅲🅷,,"Kathy Y. Yi - $SGMO Sangamo Therapeutics, Inc. - Senior VP &amp; CFO ""Okay. So let me address the $KITE $GILD Kite-Gilead #upfront for -- as you know, the #HSR did not clear until #April, which is in #Q2.""  https://t.co/lbfGneg4Ot",en,[],[],['https://pbs.twimg.com/media/DcwrpvaWkAA28WA.jpg'],2,2,9,"['upfront', 'hsr', 'april', 'q2']","['sgmo', 'kite', 'gild']",https://twitter.com/_B_I_O_T_E_C_H_/status/994217623712870400,False,,1,https://pbs.twimg.com/media/DcwrpvaWkAA28WA.jpg,,,,,,,[],,,,
991422726014423042,991422726014423042,2018-05-02 02:32:52 IST,2018-05-02,02:32:52,+0530,102754598,johncendpts,John Carroll,,#3 Gilead joins the lineup of big biopharma partners to ally with Verily — this time focused on immunology $GILD  https://t.co/austsLDo3T,en,[],['https://endpts.com/gilead-joins-the-lineup-of-big-biopharma-partners-to-ally-with-verily-this-time-focused-on-immunology/'],[],0,2,5,[],['gild'],https://twitter.com/JohnCendpts/status/991422726014423042,False,,0,,,,,,,,[],,,,
991262539223896064,991262539223896064,2018-05-01 15:56:20 IST,2018-05-01,15:56:20,+0530,102754598,johncendpts,John Carroll,,Gilead joins the lineup of big biopharma partners to ally with Verily — this time focused on immunology $GILD  https://t.co/austsLDo3T,en,[],['https://endpts.com/gilead-joins-the-lineup-of-big-biopharma-partners-to-ally-with-verily-this-time-focused-on-immunology/'],[],0,1,8,[],['gild'],https://twitter.com/JohnCendpts/status/991262539223896064,False,,0,,,,,,,,[],,,,
989034399026110464,989034399026110464,2018-04-25 12:22:30 IST,2018-04-25,12:22:30,+0530,4859660471,_b_i_o_t_e_c_h_,🅱🅸🅾🆃🅴🅲🅷,,"$GILD says wants a stake in $SGMO ""#Gilead Sciences, Inc. has indicated an interest in #purchasing up to approximately $50,000,000 of the shares of common stock offered hereby at the price offered to the public"" nice underwriters BTW BofAML JPM  https://t.co/NG3y1IJGUH",en,[],[],['https://pbs.twimg.com/media/DbnBV9aWsAEaOaR.jpg'],7,14,35,"['gilead', 'purchasing']","['gild', 'sgmo']",https://twitter.com/_B_I_O_T_E_C_H_/status/989034399026110464,False,,1,https://pbs.twimg.com/media/DbnBV9aWsAEaOaR.jpg,,,,,,,[],,,,
988780245300981760,988780245300981760,2018-04-24 19:32:35 IST,2018-04-24,19:32:35,+0530,3220653739,imakglobal,I-MAK,,Goldman says “Gilead has exhausted the available pool of treatable [#hepC] patients.” NOT. TRUE. An astounding 85% of already-diagnosed patients in the U.S. have NOT yet received treatment. That’s more than the combined total $GILD has treated to date.  https://t.co/o3yfpRnDpX,en,[],['https://www.cnbc.com/2018/04/11/goldman-asks-is-curing-patients-a-sustainable-business-model.html'],[],1,6,9,['hepc'],['gild'],https://twitter.com/IMAKglobal/status/988780245300981760,False,,0,,,,,,,,[],,,,
987356051379978240,987356051379978240,2018-04-20 21:13:21 IST,2018-04-20,21:13:21,+0530,13171622,pharmalot,pharmalot,,NIH is sued over plans to award an exclusive license for a CAR-T therapy to Gilead.. read lawsuit here..  https://t.co/ra3PsYT7gm #pharma $GILD $NVS #cancer #patents #NIH,en,[],['https://www.statnews.com/pharmalot/2018/04/20/nih-sued-license-gilead-car-t/'],[],1,13,13,"['pharma', 'cancer', 'patents', 'nih']","['gild', 'nvs']",https://twitter.com/pharmalot/status/987356051379978240,False,,0,,,,,,,,[],,,,
984811454380601344,984811454380601344,2018-04-13 20:42:02 IST,2018-04-13,20:42:02,+0530,4859660471,_b_i_o_t_e_c_h_,🅱🅸🅾🆃🅴🅲🅷,,"$XBI $IBB $NBI #BIOTECH Biotechnology: 2018 American Association for Cancer Research Annual Meeting #AACR18  As one of the future focuses, off-the-shelf cell therapy CAR-T has gained significant attention lately, as evidenced by $GILD Gilead’s $3.2 Billion deal with Sangamo $SGMO  https://t.co/KGj8NrtC2v",en,[],[],"['https://pbs.twimg.com/media/DarAoxyXkAAzG48.jpg', 'https://pbs.twimg.com/media/DarAprdXUAAD-au.jpg']",2,7,18,"['biotech', 'aacr18']","['xbi', 'ibb', 'nbi', 'gild', 'sgmo']",https://twitter.com/_B_I_O_T_E_C_H_/status/984811454380601344,False,,1,https://pbs.twimg.com/media/DarAoxyXkAAzG48.jpg,,,,,,,[],,,,
983706542733189120,983706542733189120,2018-04-10 19:31:30 IST,2018-04-10,19:31:30,+0530,4859660471,_b_i_o_t_e_c_h_,🅱🅸🅾🆃🅴🅲🅷,,"$SGMO should start to PR patents ... just like bigmouth $CLLS does .. talking about they would license and such ... maybe NY-ESO1 already a partnered asset into $GILD $KITE , Gilead will sue the shit out of any infringment of $SGMO patents !!!  https://t.co/XlfZtU5Wov",en,[],['https://twitter.com/_B_I_O_T_E_C_H_/status/983647594072158208'],[],1,4,7,[],"['sgmo', 'clls', 'gild', 'kite', 'sgmo']",https://twitter.com/_B_I_O_T_E_C_H_/status/983706542733189120,False,https://twitter.com/_B_I_O_T_E_C_H_/status/983647594072158208,0,,,,,,,,[],,,,
978413803867123712,978413803867123712,2018-03-27 05:00:03 IST,2018-03-27,05:00:03,+0530,102754598,johncendpts,John Carroll,,Revenue down? No worries for Gilead CEO Milligan as compensation swells to $15.4M $GILD $PFE etc  https://t.co/UpQo9FboKo,en,[],['https://endpts.com/revenue-down-no-worries-for-gilead-ceo-milligan-as-compensation-swells-to-15-4m/'],[],3,5,7,[],"['gild', 'pfe']",https://twitter.com/JohnCendpts/status/978413803867123712,False,,0,,,,,,,,[],,,,
975735720370466816,975735720370466816,2018-03-19 19:38:18 IST,2018-03-19,19:38:18,+0530,795618706743300096,biotech_junkie,Gene Editing,,"$GILD spent even more on $Kite in 2018, recently announcing a collaboration with Sangamo Therapeutics $SGMO  worth up to $3 billion for its gene editing technology. These moves  while costly, positions Gilead as a future leader in cell therapy   https://t.co/7yxlIk0D1W",en,[],['https://seekingalpha.com/article/4157512-biotech-bio-series-2-gilead-still-growth-stock'],[],1,5,10,[],"['gild', 'kite', 'sgmo']",https://twitter.com/biotech_junkie/status/975735720370466816,False,,0,,,,,,,,[],,,,
973272907249082370,973272907249082370,2018-03-13 00:31:58 IST,2018-03-13,00:31:58,+0530,102754598,johncendpts,John Carroll,,"One of the best R&amp;D groups in terms of execution -- Gilead R&amp;D chief Norbert Bischofberger is leaving in surprise exit, CEO revamps top science jobs $GILD  https://t.co/mgmmZIYhSv",en,[],['https://endpts.com/gilead-rd-chief-norbert-bischofberger-is-leaving-in-surprise-exit-ceo-revamps-top-science-jobs/'],[],4,3,9,[],['gild'],https://twitter.com/JohnCendpts/status/973272907249082370,False,,0,,,,,,,,[],,,,
973248066512973826,973248066512973826,2018-03-12 22:53:15 IST,2018-03-12,22:53:15,+0530,102094857,adamfeuerstein,Adam Feuerstein,,End of an era: Gilead’s longtime R&amp;D chief is stepping down at a pivotal moment for the company  https://t.co/eQ2q3UOvkL via @RebeccaDRobbins $GILD,en,"[{'screen_name': 'rebeccadrobbins', 'name': 'rebecca robbins', 'id': '368158573'}]",['https://www.statnews.com/2018/03/12/gilead-bischofberger/'],[],0,5,10,[],['gild'],https://twitter.com/adamfeuerstein/status/973248066512973826,False,,0,,,,,,,,[],,,,
973203343253393409,973203341638619136,2018-03-12 19:55:32 IST,2018-03-12,19:55:32,+0530,4859660471,_b_i_o_t_e_c_h_,🅱🅸🅾🆃🅴🅲🅷,,"also: In his new role as Chief Medical Officer, Dr. Cheng will retain  leadership of $GILD HIV clinical research program and will  assume responsibility for Gilead’s Medical Affairs organization. whats up with that zinc finger program in HIV with that 100+ patients  .. $SGMO ?",en,[],[],[],1,3,5,[],"['gild', 'sgmo']",https://twitter.com/_B_I_O_T_E_C_H_/status/973203343253393409,False,,0,,,,,,,,[],,,,
973203341638619136,973203341638619136,2018-03-12 19:55:32 IST,2018-03-12,19:55:32,+0530,4859660471,_b_i_o_t_e_c_h_,🅱🅸🅾🆃🅴🅲🅷,,"when John McHutchison, the current EVP of clinical research takes over at $GILD (now he is responsible for Gilead’s development programs in #liver diseases, #hematology and #oncology, and #inflammatory and respiratory ) dont you think this would speed up more $SGMO deals ?",en,[],[],[],1,4,4,"['liver', 'hematology', 'oncology', 'inflammatory']","['gild', 'sgmo']",https://twitter.com/_B_I_O_T_E_C_H_/status/973203341638619136,False,,0,,,,,,,,[],,,,
973122967378038784,973122008916660224,2018-03-12 14:36:09 IST,2018-03-12,14:36:09,+0530,4859660471,_b_i_o_t_e_c_h_,🅱🅸🅾🆃🅴🅲🅷,,@BLLPHD @WIRED @WiredUK 13:00 - 13:45 Partner Panel: The Future of HIV: What's Next? Co-Hosted by Gilead  $GILD ( $SGMO  )   https://t.co/PByz1NHHGj,en,[],['http://www.wired.co.uk/article/wired-health-2018-agenda'],[],1,4,5,[],"['gild', 'sgmo']",https://twitter.com/_B_I_O_T_E_C_H_/status/973122967378038784,False,,0,,,,,,,,"[{'screen_name': 'BLLPHD', 'name': 'Bruce Levine, Ph.D.', 'id': '211353183'}, {'screen_name': 'WIRED', 'name': 'WIRED', 'id': '1344951'}, {'screen_name': 'WiredUK', 'name': 'WIRED UK', 'id': '22363802'}]",,,,
971340922389704704,971340922389704704,2018-03-07 16:34:57 IST,2018-03-07,16:34:57,+0530,4859660471,_b_i_o_t_e_c_h_,🅱🅸🅾🆃🅴🅲🅷,,"Analyst asks $EDIT if Gilead $GILD thought going with #zinc #finger would be a safer bet ""I'm just trying to get some color on what are your thoughts on why they made that decision?"" $EDIT answers: ""you should talk to them about why they made the choices they may have made"" NFQ",en,[],[],[],1,4,9,"['zinc', 'finger']","['edit', 'gild', 'edit']",https://twitter.com/_B_I_O_T_E_C_H_/status/971340922389704704,False,,0,,,,,,,,[],,,,
971026145373286405,971026145373286405,2018-03-06 19:44:08 IST,2018-03-06,19:44:08,+0530,102754598,johncendpts,John Carroll,,"Searching for HIV cure, Gilead’s new ‘shock and kill’ combo swats back lethal virus in monkeys $GILD  https://t.co/4kTAPVCm2G",en,[],['https://endpts.com/searching-for-hiv-cure-harvard-team-marks-the-success-of-gileads-new-shock-and-kill-combo-in-monkeys/'],[],1,5,7,[],['gild'],https://twitter.com/JohnCendpts/status/971026145373286405,False,,0,,,,,,,,[],,,,
968190183488278528,968190183488278528,2018-02-26 23:55:02 IST,2018-02-26,23:55:02,+0530,4859660471,_b_i_o_t_e_c_h_,🅱🅸🅾🆃🅴🅲🅷,,"Is $GILD Gilead Sciences’ new interest in the older tech a sign of renewed  momentum for $SGMO zinc finger nucleases, or just a  #lack of #confidence in  #CRISPR?  https://t.co/vQmFbXWGvl",en,[],['https://www.firstwordpharma.com/footer/benefits?tsid=17'],[],1,2,8,"['lack', 'confidence', 'crispr']","['gild', 'sgmo']",https://twitter.com/_B_I_O_T_E_C_H_/status/968190183488278528,False,,0,,,,,,,,[],,,,
967385716643827717,967385716643827717,2018-02-24 18:38:22 IST,2018-02-24,18:38:22,+0530,102754598,johncendpts,John Carroll,,Top 5 for the week: #1 - the gene editing surprise -- All in: Gilead maps a $3.15B gene editing alliance with Sangamo for off-the-shelf CAR-T drugs $GILD $SGMO   https://t.co/q2qfG1rmQZ,en,[],['https://endpts.com/all-in-gilead-maps-a-3-15b-alliance-with-sangamo-for-off-the-shelf-car-t-drugs/'],[],1,12,21,[],"['gild', 'sgmo']",https://twitter.com/JohnCendpts/status/967385716643827717,False,,0,,,,,,,,[],,,,
967318793327439872,967318793327439872,2018-02-24 14:12:26 IST,2018-02-24,14:12:26,+0530,4859660471,_b_i_o_t_e_c_h_,🅱🅸🅾🆃🅴🅲🅷,,How $GILD Gilead Sciences Is Betting Big on $SGMO Gene Editing -   https://t.co/BJiG3eOdKX via @madisondotcom,en,"[{'screen_name': 'madisondotcom', 'name': 'madison.com', 'id': '23828118'}]",['http://host.madison.com/business/investment/markets-and-stocks/how-gilead-sciences-is-betting-big-on-gene-editing/article_8c3dab37-4c03-58d6-8b3b-0c7ed2b95fdb.html?utm_medium=social&utm_source=twitter&utm_campaign=user-share'],[],0,1,8,[],"['gild', 'sgmo']",https://twitter.com/_B_I_O_T_E_C_H_/status/967318793327439872,False,,0,,,,,,,,[],,,,
966742567667806209,966742567667806209,2018-02-23 00:02:43 IST,2018-02-23,00:02:43,+0530,4859660471,_b_i_o_t_e_c_h_,🅱🅸🅾🆃🅴🅲🅷,,JPM had chance to catch up with $GILD GILD believes ZFNs are superior to other gene editing modalities. Gilead noted to us that they believe $SGMO ZFNs are potentially #superior to other gene editing platforms based on precision efficiency andspecificity #CRISPR $EDIT $NTLA $CRSP  https://t.co/DQD8d0TSAe,en,[],[],['https://pbs.twimg.com/media/DWqPOtNX0AAKj8Y.jpg'],0,11,18,"['superior', 'crispr']","['gild', 'sgmo', 'edit', 'ntla', 'crsp']",https://twitter.com/_B_I_O_T_E_C_H_/status/966742567667806209,False,,1,https://pbs.twimg.com/media/DWqPOtNX0AAKj8Y.jpg,,,,,,,[],,,,
966722423239430144,966722423239430144,2018-02-22 22:42:41 IST,2018-02-22,22:42:41,+0530,32450040,evaluatevantage,Evaluate Vantage,,Vantage Snippet- Gilead gives Crispr the Zinc finger $GILD $SGMO  https://t.co/e3pcFyHnkg,en,[],[],['https://pbs.twimg.com/media/DWp8p4RW4AA5xld.jpg'],3,16,37,[],"['gild', 'sgmo']",https://twitter.com/evaluatevantage/status/966722423239430144,False,,1,https://pbs.twimg.com/media/DWp8p4RW4AA5xld.jpg,,,,,,,[],,,,
966698080383979521,966698080383979521,2018-02-22 21:05:57 IST,2018-02-22,21:05:57,+0530,4859660471,_b_i_o_t_e_c_h_,🅱🅸🅾🆃🅴🅲🅷,,"BMO sees it: ""... hyper-focus for $GILD Gilead given there are other potential applications (namely, #HIV) that could be explored as well, but were left out of this #initial collaboration. $SGMO  https://t.co/PTpglx9mjB",en,[],[],['https://pbs.twimg.com/media/DWpmxFxW4AARfNA.jpg'],0,6,9,"['hiv', 'initial']","['gild', 'sgmo']",https://twitter.com/_B_I_O_T_E_C_H_/status/966698080383979521,False,,1,https://pbs.twimg.com/media/DWpmxFxW4AARfNA.jpg,,,,,,,[],,,,
966681847915741184,966681847915741184,2018-02-22 20:01:27 IST,2018-02-22,20:01:27,+0530,4859660471,_b_i_o_t_e_c_h_,🅱🅸🅾🆃🅴🅲🅷,,"UBS $SGMO $KITE $GILD Gilead Makes Another Move in Cell Therapy This morning, Gilead / Kite and Sangamo (cont)  https://t.co/mR3pNPx8QF",en,[],['http://tl.gd/n_1sqeou8'],[],0,2,13,[],"['sgmo', 'kite', 'gild']",https://twitter.com/_B_I_O_T_E_C_H_/status/966681847915741184,False,,0,,,,,,,,[],,,,
966667800499687424,966667800499687424,2018-02-22 19:05:38 IST,2018-02-22,19:05:38,+0530,1330055544,benthefidler,Ben Fidler,,"Continuing Cell Therapy Push, Gilead Aligns with Sangamo for CAR-T Boost  https://t.co/iDiIYZdBgy $GILD $NVS $CELG $SGMO $NTLA $EDIT",en,[],['https://www.xconomy.com/san-francisco/2018/02/22/continuing-cell-therapy-push-gilead-aligns-with-sangamo-for-car-t-boost/'],[],2,1,8,[],"['gild', 'nvs', 'celg', 'sgmo', 'ntla', 'edit']",https://twitter.com/BentheFidler/status/966667800499687424,False,,0,,,,,,,,[],,,,
966655119096983553,966655119096983553,2018-02-22 18:15:14 IST,2018-02-22,18:15:14,+0530,4859660471,_b_i_o_t_e_c_h_,🅱🅸🅾🆃🅴🅲🅷,,Sangamo $SGMO $Kite / Gilead $GILD deal economics  https://t.co/JQxELa5i2h,tl,[],[],['https://pbs.twimg.com/media/DWo_sbYX0AAsOZA.jpg'],3,9,18,[],"['sgmo', 'kite', 'gild']",https://twitter.com/_B_I_O_T_E_C_H_/status/966655119096983553,False,,1,https://pbs.twimg.com/media/DWo_sbYX0AAsOZA.jpg,,,,,,,[],,,,
966650801438576641,966650801438576641,2018-02-22 17:58:05 IST,2018-02-22,17:58:05,+0530,102754598,johncendpts,John Carroll,,All in: Gilead maps a $3.15B gene editing alliance with Sangamo for off-the-shelf CAR-T drugs $GILD $CELG $NVS  https://t.co/q2qfG1rmQZ,en,[],['https://endpts.com/all-in-gilead-maps-a-3-15b-alliance-with-sangamo-for-off-the-shelf-car-t-drugs/'],[],3,22,48,[],"['gild', 'celg', 'nvs']",https://twitter.com/JohnCendpts/status/966650801438576641,False,,0,,,,,,,,[],,,,
965390920182050816,965390920182050816,2018-02-19 06:31:46 IST,2018-02-19,06:31:46,+0530,51932290,lin_ling_88,Helen Ong,,$GILD: A federal judge in Delaware has overturned a jury's verdict requiring Gilead Sciences Inc to pay a record $2.54 billion because its hepatitis C drugs Sovaldi and Harvoni infringed a patent held by rival Merck &amp; Co Inc.  $MRK lost the case.  https://t.co/t19Bq6kl0N,en,[],['https://finance.yahoo.com/news/gilead-wins-reversal-2-54-171822426.html;_ylc=X1MDMTE5Nzc4NDE4NQRfZXgDMQRfeXJpZANhdnFuYmgxZDhrOGNrBGcDZFhWcFpEeHVjejQzTldSbU1EVmhNaTAxTVRFd0xUTmlNR0l0T1dNM1l5MWtaVEJpTldSaU1ESmlZalIxZFdsa1BHNXpQazFTU3c9PQ0KBGxhbmcDZW4tVVMEb3JpZ19sYW5nA2VuBG9yaWdfcmVnaW9uA1VTBHBvcwMwBHJlZ2lvbgNVUwRzeW1ib2wDTVJL?.tsrc=applewf'],[],0,0,4,[],"['gild', 'mrk']",https://twitter.com/Lin_ling_88/status/965390920182050816,False,,0,,,,,,,,[],,,,
964919122667737088,964919122667737088,2018-02-17 23:17:00 IST,2018-02-17,23:17:00,+0530,3290364847,statnews,STAT,,A federal judge overturned an order that Gilead Sciences (GILD) must pay $2.5 billion in the largest ever U.S. patent dispute.  https://t.co/yFtKPTaSBI,en,[],['https://buff.ly/2Fai4Sh'],[],0,13,13,[],[],https://twitter.com/statnews/status/964919122667737088,False,,0,,,,,,,,[],,,,
964918634970787841,964918634970787841,2018-02-17 23:15:04 IST,2018-02-17,23:15:04,+0530,13171622,pharmalot,pharmalot,,A reversal of fortunes: Judge voids order that Gilead must pay $2.5B to Merck over a patent dispute.. read ruling here:  https://t.co/1lCtHkjuiU #pharma #patents $MRK $GILD #hepatitisC,en,[],['https://www.statnews.com/pharmalot/2018/02/17/merck-gilead-patents-hepatitis-litigation/'],[],0,23,18,"['pharma', 'patents', 'hepatitisc']","['mrk', 'gild']",https://twitter.com/pharmalot/status/964918634970787841,False,,0,,,,,,,,[],,,,
964186804407676930,964186804407676930,2018-02-15 22:47:02 IST,2018-02-15,22:47:02,+0530,4859660471,_b_i_o_t_e_c_h_,🅱🅸🅾🆃🅴🅲🅷,,thefool thinks $PFE Pfizer will buyout Sangamo $SGMO   3 Great Acquisition Targets for Gilead Sciences -- and 1 Iffy Candidate  These small biotechs are great fits for Gilead. But that doesn't mean the big biotech will buy them.   https://t.co/OAufChsmXJ $GILD $CELG $KITE $JUNO,en,[],['https://www.fool.com/investing/2018/02/15/3-great-acquisition-targets-for-gilead-sciences-an.aspx'],[],2,3,11,[],"['pfe', 'sgmo', 'gild', 'celg', 'kite', 'juno']",https://twitter.com/_B_I_O_T_E_C_H_/status/964186804407676930,False,,0,,,,,,,,[],,,,
961510517792739328,961510517792739328,2018-02-08 13:32:26 IST,2018-02-08,13:32:26,+0530,4859660471,_b_i_o_t_e_c_h_,🅱🅸🅾🆃🅴🅲🅷,,$GILD - $GSK GLAXOSMITHKLINE  PLC - VIIV ‍ANNOUNCED IT FILED PATENT INFRINGEMENT LITIGATION AGAINST  GILEAD SCIENCES INC. OVER BICTEGRAVIR IN UNITED STATES AND CANADA​   who will get the $SGMO  HIV  deal ???  #FIGHT,en,[],[],[],0,2,9,['fight'],"['gild', 'gsk', 'sgmo']",https://twitter.com/_B_I_O_T_E_C_H_/status/961510517792739328,False,,0,,,,,,,,[],,,,
961378572958134272,961378572958134272,2018-02-08 04:48:08 IST,2018-02-08,04:48:08,+0530,4859660471,_b_i_o_t_e_c_h_,🅱🅸🅾🆃🅴🅲🅷,,Reuters: Gene-editing cos rise on $GILD Gilead's interest in technology  https://t.co/WMz3cGMYnj,en,[],[],['https://pbs.twimg.com/media/DVeApTLXUAAznfv.jpg'],1,3,8,[],['gild'],https://twitter.com/_B_I_O_T_E_C_H_/status/961378572958134272,False,,1,https://pbs.twimg.com/media/DVeApTLXUAAznfv.jpg,,,,,,,[],,,,
961357080119607298,961357080119607298,2018-02-08 03:22:43 IST,2018-02-08,03:22:43,+0530,102754598,johncendpts,John Carroll,,$GSK files HIV patent suit -- UPDATED: Gilead gets a blockbuster boost from an FDA OK of HIV triplet Biktarvy — and rival GSK fires back $GILD  https://t.co/4o9XoL7KO1,en,[],['https://endpts.com/with-hep-c-cash-dwindling-gilead-gets-a-blockbuster-boost-from-an-fda-ok-of-hiv-triplet-biktarvy/'],[],0,6,8,[],"['gsk', 'gild']",https://twitter.com/JohnCendpts/status/961357080119607298,False,,0,,,,,,,,[],,,,
961324525706194947,961324525706194947,2018-02-08 01:13:22 IST,2018-02-08,01:13:22,+0530,102754598,johncendpts,John Carroll,,"It's on! With hep C cash dwindling, Gilead gets a blockbuster boost from an FDA OK of HIV triplet Biktarvy $GILD $GSK  https://t.co/4o9XoL7KO1",en,[],['https://endpts.com/with-hep-c-cash-dwindling-gilead-gets-a-blockbuster-boost-from-an-fda-ok-of-hiv-triplet-biktarvy/'],[],1,2,10,[],"['gild', 'gsk']",https://twitter.com/JohnCendpts/status/961324525706194947,False,,0,,,,,,,,[],,,,
958312676899414016,958312676899414016,2018-01-30 17:45:21 IST,2018-01-30,17:45:21,+0530,801116888,cfromhertz,Christian Fromhertz,,$GILD Gilead Upgraded to Buy at Citi; PT $103 from $81 via BBG  https://t.co/MkO1w5yD3Z,en,[],[],['https://pbs.twimg.com/media/DUycS3NVwAAudNP.jpg'],1,1,5,[],['gild'],https://twitter.com/cfromhertz/status/958312676899414016,False,,1,https://pbs.twimg.com/media/DUycS3NVwAAudNP.jpg,,,,,,,[],,,,
958029559500279808,958029559500279808,2018-01-29 23:00:20 IST,2018-01-29,23:00:20,+0530,475524030,wallstjesus,JE$US,,$GILD REPEAT MOMO-SWEEPERS ALL OVER GILEAD CALLS TODAY,en,[],[],[],1,6,13,[],['gild'],https://twitter.com/WallStJesus/status/958029559500279808,False,,0,,,,,,,,[],,,,
956912441463537666,956907426170761216,2018-01-26 21:01:19 IST,2018-01-26,21:01:19,+0530,89491245,bret_jensen,Bret Jensen,,@JohnCendpts $ABBV $GILD Actually what is ridiculous is they have almost quadrupled price over past decade and press has not targeted that while pillorying Gilead for providing a cure for about same price as one year maintenance on Humira,en,[],[],[],2,1,10,[],"['abbv', 'gild']",https://twitter.com/bret_jensen/status/956912441463537666,False,,0,,,,,,,,"[{'screen_name': 'JohnCendpts', 'name': 'John Carroll', 'id': '102754598'}]",,,,
953997541225443329,953997541225443329,2018-01-18 19:58:32 IST,2018-01-18,19:58:32,+0530,102754598,johncendpts,John Carroll,,"Beefing up its CAR-T pipeline, Gilead teams up with Pfizer on a lymphoma combo $GILD $PFE $NVS  https://t.co/BRhOcZzFd3",en,[],['https://endpts.com/beefing-up-its-car-t-pipeline-gilead-teams-up-with-pfizer-on-a-lymphoma-combo/'],[],0,2,11,[],"['gild', 'pfe', 'nvs']",https://twitter.com/JohnCendpts/status/953997541225443329,False,,0,,,,,,,,[],,,,
953240191308914688,953240191308914688,2018-01-16 17:49:06 IST,2018-01-16,17:49:06,+0530,801116888,cfromhertz,Christian Fromhertz,,$GILD Gilead Upgraded to Outperform at Wells Fargo; PT $96 from $84 via BBG  https://t.co/U9HMn8P6bD,en,[],[],['https://pbs.twimg.com/media/DTqW5XPUQAAVjnU.jpg'],0,4,7,[],['gild'],https://twitter.com/cfromhertz/status/953240191308914688,False,,1,https://pbs.twimg.com/media/DTqW5XPUQAAVjnU.jpg,,,,,,,[],,,,
952914264985165825,952914264985165825,2018-01-15 20:13:59 IST,2018-01-15,20:13:59,+0530,204564525,biostockaddict,BioStockAddict,,Filgotinib RA trial patient story as of 01/12.   Feel free to retweet. #rheumatoidarthritis #Galapagos #Gilead $GLPG $GILD  https://t.co/hGgFvEI2FD,en,[],[],"['https://pbs.twimg.com/media/DTludhhW0AAg0HQ.jpg', 'https://pbs.twimg.com/media/DTludhhXcAAHzq8.jpg']",4,18,24,"['rheumatoidarthritis', 'galapagos', 'gilead']","['glpg', 'gild']",https://twitter.com/BioStockAddict/status/952914264985165825,False,,1,https://pbs.twimg.com/media/DTludhhW0AAg0HQ.jpg,,,,,,,[],,,,
951268573892235264,951268573892235264,2018-01-11 07:14:36 IST,2018-01-11,07:14:36,+0530,906328017986899968,the_chart_life,"Ian McMillan, CMT",,"$GILD Gilead ...Coming back to LT trend line, after a breakout from walling wedge.  https://t.co/4nvhAE5PUf",en,[],[],['https://pbs.twimg.com/media/DTOVualX4AEn8f2.jpg'],1,1,4,[],['gild'],https://twitter.com/the_chart_life/status/951268573892235264,False,,1,https://pbs.twimg.com/media/DTOVualX4AEn8f2.jpg,,,,,,,[],,,,
950513470113394689,950513470113394689,2018-01-09 05:14:05 IST,2018-01-09,05:14:05,+0530,2701355767,brittanymeiling,Brittany Meiling,,Gilead CEO John Milligan says he expects Hep C pricing will stabilize in 2018 and beyond. $GILD #JPMHC18 #JPM18,en,[],[],[],0,6,8,"['jpmhc18', 'jpm18']",['gild'],https://twitter.com/BrittanyMeiling/status/950513470113394689,False,,0,,,,,,,,[],,,,
946073603283521536,946073603283521536,2017-12-27 23:11:38 IST,2017-12-27,23:11:38,+0530,61342056,optionshawk,Joe Kunkle,,"Gilead $GILD with 2,000 January $71 calls ITM bought to open $3.05 offer, bouncing at 200 MA",en,[],[],[],2,4,19,[],['gild'],https://twitter.com/OptionsHawk/status/946073603283521536,False,,0,,,,,,,,[],,,,
942819570552893440,942819570552893440,2017-12-18 23:41:17 IST,2017-12-18,23:41:17,+0530,13171622,pharmalot,pharmalot,,Gilead faces a patent challenge to Epclusa in China by Doctors Without Borders..  https://t.co/B40GWpkNHZ #pharma #patents $GILD,en,[],['https://www.statnews.com/pharmalot/2017/12/18/gilead-hepatitis-patents-msf/'],[],1,1,7,"['pharma', 'patents']",['gild'],https://twitter.com/pharmalot/status/942819570552893440,False,,0,,,,,,,,[],,,,
941365503758622721,941365503758622721,2017-12-14 23:23:20 IST,2017-12-14,23:23:20,+0530,1407780158,drmiguelperales,Miguel Perales M.D.,,"Cancer patients with little time left waiting for potential breakthrough drug from Gilead (Yescarta): ""No Medicare coverage, one-by-one rulings by private insurers"" - Will take @cmsgov a while to fix #CARTcell $KITE $GILD #FinancialToxicity   https://t.co/BdND2bxKlM via @business",en,"[{'screen_name': 'cmsgov', 'name': 'cmsgov', 'id': '70837868'}, {'screen_name': 'business', 'name': 'bloomberg', 'id': '34713362'}]",['https://www.bloomberg.com/news/articles/2017-12-14/cancer-patients-with-little-time-left-wait-for-gilead-s-new-drug'],[],1,9,13,"['cartcell', 'financialtoxicity']","['kite', 'gild']",https://twitter.com/DrMiguelPerales/status/941365503758622721,False,,0,,,,,,,,[],,,,
941299190533120000,941299190533120000,2017-12-14 18:59:50 IST,2017-12-14,18:59:50,+0530,57124794,annaedney,Anna Edney,,Billing issues are keeping dying patients from getting Gilead's life-saving new cancer treatment  https://t.co/Ybvjk2EuSC by @FayCortez @CarolineYLChen @n_rausch21 $GILD,en,"[{'screen_name': 'faycortez', 'name': 'michelle fay cortez', 'id': '295746612'}, {'screen_name': 'carolineylchen', 'name': 'caroline chen', 'id': '576436187'}]",['https://www.bloomberg.com/news/articles/2017-12-14/cancer-patients-with-little-time-left-wait-for-gilead-s-new-drug'],[],1,6,6,[],['gild'],https://twitter.com/annaedney/status/941299190533120000,False,,0,,,,,,,,[],,,,
939880640085979136,939880640085979136,2017-12-10 21:03:01 IST,2017-12-10,21:03:01,+0530,102754598,johncendpts,John Carroll,,-- #ASH17: How does Novartis’ Kymriah DLBCL data stack up heading straight to a CAR-T showdown with Gilead? $NVS $GILD   https://t.co/5PEZQIVVHr,en,[],['https://endpts.com/ash17-how-does-novartis-kymriah-dlbcl-data-stack-up-heading-straight-to-a-car-t-showdown-with-gilead/'],[],0,7,11,['ash17'],"['nvs', 'gild']",https://twitter.com/JohnCendpts/status/939880640085979136,False,,0,,,,,,,,[],,,,
939566878095282178,818574597993828352,2017-12-10 00:16:14 IST,2017-12-10,00:16:14,+0530,146342882,pakbenikasim,🅟🅐🅚,,"Actualización:  Gilead $GILD Mylan $MYL Biogen $BIIB Perrigo $PRGO  Tanto Gilead como Biogen se movieron al alza y están para iniciar un nuevo impulso, pero Perrigo y Mylan siguen en un punto muy similar trabajando el comienzo alcista  #bolsa  https://t.co/UNuLWooqrL",es,[],[],"['https://pbs.twimg.com/media/DQoC_phW4AATHp6.jpg', 'https://pbs.twimg.com/media/DQoC_pIWkAA3mOQ.jpg', 'https://pbs.twimg.com/media/DQoC_pyW4AIR5Wv.jpg', 'https://pbs.twimg.com/media/DQoC_puXkAAHuKt.jpg']",0,3,14,['bolsa'],"['gild', 'myl', 'biib', 'prgo']",https://twitter.com/PakBenikasim/status/939566878095282178,False,,1,https://pbs.twimg.com/media/DQoC_phW4AATHp6.jpg,,,,,,,[],,,,
938898310487838721,938898310487838721,2017-12-08 03:59:35 IST,2017-12-08,03:59:35,+0530,102754598,johncendpts,John Carroll,,#cooltech! Gilead swoops in with $567M deal to buy CAR-T 2.0 player Cell Design Labs $GILD $NVS  https://t.co/8rDZsAQSe1,en,[],['https://endpts.com/gilead-swoops-in-with-567m-deal-to-buy-car-t-2-0-player-cell-design-labs/'],[],3,12,32,['cooltech'],"['gild', 'nvs']",https://twitter.com/JohnCendpts/status/938898310487838721,False,,0,,,,,,,,[],,,,
938891980611969024,938891980611969024,2017-12-08 03:34:26 IST,2017-12-08,03:34:26,+0530,3109094919,rvh_investing,RVH_Investing,,$GILD Gilead Sciences to Acquire Cell Design Labs for $567M,en,[],[],[],0,1,6,[],['gild'],https://twitter.com/RVH_Investing/status/938891980611969024,False,,0,,,,,,,,[],,,,
923879789584441344,923879789584441344,2017-10-27 17:21:21 IST,2017-10-27,17:21:21,+0530,102754598,johncendpts,John Carroll,,"First Celgene, now Gilead can’t accurately forecast drug sales revenue. How bad is this? $CELG $GILD  https://t.co/qu9m9yyNbj",en,[],['https://endpts.com/first-celgene-now-gilead-cant-accurately-forecast-drug-sales-revenue-whats-up-with-that/'],[],1,5,15,[],"['celg', 'gild']",https://twitter.com/JohnCendpts/status/923879789584441344,False,,0,,,,,,,,[],,,,
923814563136638976,915203107155529728,2017-10-27 13:02:10 IST,2017-10-27,13:02:10,+0530,4859660471,_b_i_o_t_e_c_h_,🅱🅸🅾🆃🅴🅲🅷,,"@Biotech2050 @bradloncar Barclays says: $GILD GILEAD MAY ADD ASSETS TO ACCELERATE ITS ¢ar-t SOLID TUMOR AND BROADER ONCOLOGY EFFORTS, / 100% fit = $SGMO even for HIV  https://t.co/IQsZweULiL",en,[],[],"['https://pbs.twimg.com/media/DNIMY_pX4AAMmes.jpg', 'https://pbs.twimg.com/media/DNIMZ8RX0AAGGV2.jpg']",1,3,8,[],"['gild', 'sgmo']",https://twitter.com/_B_I_O_T_E_C_H_/status/923814563136638976,False,,1,https://pbs.twimg.com/media/DNIMY_pX4AAMmes.jpg,,,,,,,"[{'screen_name': 'Biotech2050', 'name': 'Biotech2050 💎✋', 'id': '2494896473'}, {'screen_name': 'bradloncar', 'name': 'Brad Loncar', 'id': '274233761'}]",,,,
923251624205799424,923251624205799424,2017-10-25 23:45:15 IST,2017-10-25,23:45:15,+0530,4859660471,_b_i_o_t_e_c_h_,🅱🅸🅾🆃🅴🅲🅷,,80% chance $GILD Gilead sciences buys $SGMO sangamo  therapeutics in the next 6 months. for $KITE addon and HBV  https://t.co/O25MPzEtoq …,en,[],['https://www.investorvillage.com/smbd.asp?mb=1933&mn=92670&pt=msg&mid=17641098'],[],4,7,19,[],"['gild', 'sgmo', 'kite']",https://twitter.com/_B_I_O_T_E_C_H_/status/923251624205799424,False,,0,,,,,,,,[],,,,
922848114540777472,922848114540777472,2017-10-24 21:01:50 IST,2017-10-24,21:01:50,+0530,3092408171,donwnicholson,Don Nicholson,,Liking $GILD press release: Gilead Announces Phase 2 Results for GS-0976 in Nonalcoholic Steatohepatitis (NASH)  https://t.co/6lGn0IKaIJ,en,[],['http://www.businesswire.com/news/home/20171024005952/en/Gilead-Announces-Phase-2-Results-GS-0976-Nonalcoholic#.We9cj_8H4eU.twitter'],[],0,2,5,[],['gild'],https://twitter.com/DonWNicholson/status/922848114540777472,False,,0,,,,,,,,[],,,,
920768032997363712,920768032997363712,2017-10-19 03:16:20 IST,2017-10-19,03:16:20,+0530,102754598,johncendpts,John Carroll,,"FDA follows through with a groundbreaking OK for Yescarta, Gilead’s new CAR-T breakthrough $GILD $NVS  https://t.co/EqiL83y5H5",en,[],['https://endpts.com/fda-follows-through-with-a-groundbreaking-ok-for-yescarta-gileads-new-car-t-breakthrough/'],[],1,20,32,[],"['gild', 'nvs']",https://twitter.com/JohnCendpts/status/920768032997363712,False,,0,,,,,,,,[],,,,
917918283583578112,917918283583578112,2017-10-11 06:32:27 IST,2017-10-11,06:32:27,+0530,97334517,allstarcharts,J.C. Parets,,"Gilead, the underperformer of all underperformers, looks like it is finally trying to make a move $GILD  https://t.co/48MJUVRZ51",en,[],[],['https://pbs.twimg.com/media/DL0ZwjkVoAAj6GL.jpg'],6,16,46,[],['gild'],https://twitter.com/allstarcharts/status/917918283583578112,False,,1,https://pbs.twimg.com/media/DL0ZwjkVoAAj6GL.jpg,,,,,,,[],,,,
912291088232210432,912291088232210432,2017-09-25 17:51:59 IST,2017-09-25,17:51:59,+0530,430841130,canuck2usa,CtheLightTrading,,$GILD - CFDA approves Gilead's Sovaldi for treatment of chronic HCV infection,en,[],[],[],0,1,6,[],['gild'],https://twitter.com/canuck2usa/status/912291088232210432,False,,0,,,,,,,,[],,,,
912284554987229184,912284554987229184,2017-09-25 17:26:01 IST,2017-09-25,17:26:01,+0530,112872946,biostocks,Bio Stocks™,,$GILD China FDA Approves Gilead's Sovaldi for Treatment of Chronic Hepatitis C Virus Infection,en,[],[],[],1,9,11,[],['gild'],https://twitter.com/BioStocks/status/912284554987229184,False,,0,,,,,,,,[],,,,
912234121627389952,912234121627389952,2017-09-25 14:05:37 IST,2017-09-25,14:05:37,+0530,4859660471,_b_i_o_t_e_c_h_,🅱🅸🅾🆃🅴🅲🅷,,MIZUHO survey: who should Gilead $GILD buy? $VRTX: 7%  $GLPG: 6%  $INCY: 6%  $ICPT: 4% (LOL) $SGMO: 4% $TSRO: 4% $ALNY: 3% $BLUE: 3%,en,[],[],[],0,3,6,[],"['gild', 'vrtx', 'glpg', 'incy', 'icpt', 'sgmo', 'tsro', 'alny', 'blue']",https://twitter.com/_B_I_O_T_E_C_H_/status/912234121627389952,False,,0,,,,,,,,[],,,,
910319425282338816,910319425282338816,2017-09-20 07:17:18 IST,2017-09-20,07:17:18,+0530,14063950,cells_nnm,Alexey Bersenev,,"$GILD COO Kevin Young: ""Gilead continues to look at further potential acquisitions in cell therapy""  https://t.co/dhl8lMTXMu",en,[],['http://host.madison.com/business/investment/markets-and-stocks/gilead-sciences-kite-pharma-deal-has-already-paid-for-itself/article_96edae92-111b-52fa-9f86-159dee00f766.html'],[],2,8,6,[],['gild'],https://twitter.com/cells_nnm/status/910319425282338816,False,,0,,,,,,,,[],,,,
905423517344256000,905423517344256000,2017-09-06 19:02:43 IST,2017-09-06,19:02:43,+0530,61342056,optionshawk,Joe Kunkle,,"Gilead $GILD early morning buys of 1,000 December $82.5 calls up to $4.56 after some sizable adds yesterday",en,[],[],[],0,2,11,[],['gild'],https://twitter.com/OptionsHawk/status/905423517344256000,False,,0,,,,,,,,[],,,,
902210637555798020,902210637555798020,2017-08-28 22:15:52 IST,2017-08-28,22:15:52,+0530,4859660471,_b_i_o_t_e_c_h_,🅱🅸🅾🆃🅴🅲🅷,,"This immediately makes $SGMO in play to $GILD Gilead, + if Gilead doesn't bite, someone else will...  https://t.co/EssOY04QaF $KITE $GSK $NVS",en,[],['https://www.investorvillage.com/smbd.asp?mb=1933&mn=90073&pt=msg&mid=17479754'],[],0,4,5,[],"['sgmo', 'gild', 'kite', 'gsk', 'nvs']",https://twitter.com/_B_I_O_T_E_C_H_/status/902210637555798020,False,,0,,,,,,,,[],,,,
902181410458480640,902181410458480640,2017-08-28 20:19:44 IST,2017-08-28,20:19:44,+0530,18294197,fiercebiotech,FierceBiotech,,"Kite's CAR-T med, pipeline draw choosy Gilead for $12B pipeline-building buyout:  https://t.co/J6bPJcaT9h $KITE $GILD",en,[],['http://ow.ly/ZFsQ30eJ7hA'],[],0,6,9,[],"['kite', 'gild']",https://twitter.com/FierceBiotech/status/902181410458480640,False,,0,,,,,,,,[],,,,
902161534889152513,902161534889152513,2017-08-28 19:00:45 IST,2017-08-28,19:00:45,+0530,18294197,fiercebiotech,FierceBiotech,,"Gilead strikes $12B takeover of Kite, boosting its cancer pipeline:  https://t.co/uipceLCJQv $GILD $KITE",en,[],['http://ow.ly/ydcx30eIYuF'],[],0,2,7,[],"['gild', 'kite']",https://twitter.com/FierceBiotech/status/902161534889152513,False,,0,,,,,,,,[],,,,
902153161544048640,902153161544048640,2017-08-28 18:27:29 IST,2017-08-28,18:27:29,+0530,174385219,mariogabelli,Mario Gabelli,,"Deals, deals and !....KITE (Kite Pharma) to be bought by Gilead (GILD) for $180 cash per share....",en,[],[],[],2,4,12,[],[],https://twitter.com/MarioGabelli/status/902153161544048640,False,,0,,,,,,,,[],,,,
902134912840601601,902134912840601601,2017-08-28 17:14:58 IST,2017-08-28,17:14:58,+0530,44438256,matthewherper,Matthew Herper,,"$GILD tells me: ""we are very impressed with the team at $Kite and hope the vast majority of employees will be a part of Gilead.""",en,[],[],[],2,4,12,[],"['gild', 'kite']",https://twitter.com/matthewherper/status/902134912840601601,False,,0,,,,,,,,[],,,,
902123984807796736,902123984807796736,2017-08-28 16:31:33 IST,2017-08-28,16:31:33,+0530,37469211,pipstodollars,Leilani Pips™,,"Gilead will pay $180 a share, the people said, representing a 29% premium over Kite's closing price Friday. $KITE $GILD  https://t.co/tBqN4wtARy",en,[],['https://twitter.com/PipsToDollars/status/902123621337841664'],[],0,1,4,[],"['kite', 'gild']",https://twitter.com/PipsToDollars/status/902123984807796736,False,https://twitter.com/PipsToDollars/status/902123621337841664,0,,,,,,,,[],,,,
902122586632593408,902122586632593408,2017-08-28 16:25:59 IST,2017-08-28,16:25:59,+0530,102754598,johncendpts,John Carroll,,"It's a $12B deal . $KITE $GILD -- Diving deep into CAR-T, Gilead forges $12B buyout deal for Kite Pharma  https://t.co/TiTEDC7Wop",en,[],['https://endpts.com/gilead-inks-deal-to-buy-car-t-leader-kite-pharma-for-11b-wsj/'],[],3,30,18,[],"['kite', 'gild']",https://twitter.com/JohnCendpts/status/902122586632593408,False,,0,,,,,,,,[],,,,
902121575411052545,902121575411052545,2017-08-28 16:21:58 IST,2017-08-28,16:21:58,+0530,3109094919,rvh_investing,RVH_Investing,,"$GILD ""LIVE""COVERAGE OF GILEAD SHAREHOLDERS REACTING TO $KITE $11B DEAL  https://t.co/BpOfaWEm8v",en,[],[],['https://pbs.twimg.com/tweet_video_thumb/DIT6yVmXUAAKZcJ.jpg'],0,1,7,[],"['gild', 'kite']",https://twitter.com/RVH_Investing/status/902121575411052545,False,,1,https://pbs.twimg.com/tweet_video_thumb/DIT6yVmXUAAKZcJ.jpg,,,,,,,[],,,,
902117897182564353,902117897182564353,2017-08-28 16:07:21 IST,2017-08-28,16:07:21,+0530,23892927,danamattioli,Dana Mattioli,,Merger Monday! Gilead is buying Kite Pharma for $11B. Scoop from @jonathanrockoff  https://t.co/2rOaLzG9JP $KITE $GILD,en,"[{'screen_name': 'jonathanrockoff', 'name': 'jonathan rockoff', 'id': '18021517'}]",['http://on.wsj.com/2ghXk2u'],[],0,13,13,[],"['kite', 'gild']",https://twitter.com/DanaMattioli/status/902117897182564353,False,,0,,,,,,,,[],,,,
895763518506577921,895763518506577921,2017-08-11 03:17:19 IST,2017-08-11,03:17:19,+0530,102754598,johncendpts,John Carroll,,Gilead circles February 12 on its calendar as D-day for its HIV franchise $GILD  https://t.co/RB25Aj3yq7,en,[],['https://endpts.com/gilead-circles-february-12-on-its-calendar-as-d-day-for-its-hiv-franchise/'],[],0,8,11,[],['gild'],https://twitter.com/JohnCendpts/status/895763518506577921,False,,0,,,,,,,,[],,,,
893427185947738112,893427185947738112,2017-08-04 16:33:34 IST,2017-08-04,16:33:34,+0530,102754598,johncendpts,John Carroll,,"Look out Gilead, AbbVie’s hep C combo comes with stellar data, 8-week regimen and a killer price $GILD $ABBV $ENTA  https://t.co/3Px16y1kxu",en,[],['https://endpts.com/look-out-gilead-abbvies-hep-c-combo-comes-with-stellar-data-8-week-regimen-and-a-killer-price/'],[],0,19,13,[],"['gild', 'abbv', 'enta']",https://twitter.com/JohnCendpts/status/893427185947738112,False,,0,,,,,,,,[],,,,
872346429519540224,872346429519540224,2017-06-07 12:26:10 IST,2017-06-07,12:26:10,+0530,4859660471,_b_i_o_t_e_c_h_,🅱🅸🅾🆃🅴🅲🅷,,"Barlays dinner with $GILD "" GILEAD HAS BEEN VERY ACTIVE BEHIND THE SCENES AND TO US, THE COMPANY SEEMS READY TO PULL THE TRIGGER "" #oncology  https://t.co/rHcFMWG95A",en,[],[],['https://pbs.twimg.com/media/DBsyNspWAAgnZny.jpg'],8,31,33,['oncology'],['gild'],https://twitter.com/_B_I_O_T_E_C_H_/status/872346429519540224,False,,1,https://pbs.twimg.com/media/DBsyNspWAAgnZny.jpg,,,,,,,[],,,,
859742976544829440,859742976544829440,2017-05-03 17:44:33 IST,2017-05-03,17:44:33,+0530,102754598,johncendpts,John Carroll,,So what’s holding back Pfizer and Gilead from the really big M&amp;A deals we’ve all been waiting for? $PFE $GILD  https://t.co/j1YSmw0ACp,en,[],['https://endpts.com/so-whats-holding-back-pfizer-and-gilead-from-the-really-big-ma-deals-weve-all-been-waiting-for/'],[],3,7,11,[],"['pfe', 'gild']",https://twitter.com/JohnCendpts/status/859742976544829440,False,,0,,,,,,,,[],,,,
855430168663531521,855430168663531521,2017-04-21 20:06:59 IST,2017-04-21,20:06:59,+0530,102754598,johncendpts,John Carroll,,Gilead offers a glimpse at hard data to back up its $600M investment in Nimbus’ NASH drug $GILD  https://t.co/xPOwlkGO3o,en,[],['https://endpts.com/gilead-offers-a-glimpse-at-hard-data-to-back-up-its-600m-investment-in-nimbus-nash-drug/'],[],0,7,8,[],['gild'],https://twitter.com/JohnCendpts/status/855430168663531521,False,,0,,,,,,,,[],,,,
849721860875063297,849721860875063297,2017-04-06 02:04:13 IST,2017-04-06,02:04:13,+0530,204564525,biostockaddict,BioStockAddict,,"Galapagos doses first psoriatic arthritis patient with filgotinib, $10M milestone payment from Gilead $GLPG $GILD  https://t.co/jwm4wsrN31",en,[],['http://hugin.info/133350/R/2094014/791667.pdf'],[],0,3,5,[],"['glpg', 'gild']",https://twitter.com/BioStockAddict/status/849721860875063297,False,,0,,,,,,,,[],,,,
849003428340805632,849003428340805632,2017-04-04 02:29:25 IST,2017-04-04,02:29:25,+0530,13171622,pharmalot,pharmalot,,Gilead loses a patent battle over Sovaldi in Brazil.. another loss amid mounting challenges..   https://t.co/R7qzJg3A8X #pharma $GILD,en,[],['https://www.statnews.com/pharmalot/2017/04/03/gilead-patent-sovaldi-brazil/'],[],0,15,7,['pharma'],['gild'],https://twitter.com/pharmalot/status/849003428340805632,False,,0,,,,,,,,[],,,,
847892806374961153,847892806374961153,2017-04-01 00:56:12 IST,2017-04-01,00:56:12,+0530,57406450,henryechang,Henry E. Chang,,"France reaches agreement with Gilead to drop prices of #HCV drug (from €41,000 to €28,700 for SOF)→ https://t.co/rtKwWwE0jM #HepC $GILD 🇫🇷",en,[],['http://ow.ly/LOip30as0Co'],[],0,7,16,"['hcv', 'hepc']",['gild'],https://twitter.com/HenryEChang/status/847892806374961153,False,,0,,,,,,,,[],,,,
847760410631655428,847760410631655428,2017-03-31 16:10:07 IST,2017-03-31,16:10:07,+0530,61342056,optionshawk,Joe Kunkle,,"Gilead $GILD afternoon spread bought 2,000 June $67.50 calls $2.86 and sold 4,000 June $62.50 puts at $0.96",en,[],[],[],0,6,18,[],['gild'],https://twitter.com/OptionsHawk/status/847760410631655428,False,,0,,,,,,,,[],,,,
841816221490147328,841816221490147328,2017-03-15 06:30:02 IST,2017-03-15,06:30:02,+0530,44060322,benzinga,Benzinga,,Gilead Looking To Buy Incyte? It Makes Sense  https://t.co/z8qZ26Ucj6 $GILD $INCY $KITE,en,[],['https://benzinga.com/z/9169178'],[],0,1,7,[],"['gild', 'incy', 'kite']",https://twitter.com/Benzinga/status/841816221490147328,False,,0,,,,,,,,[],,,,
840938600875347970,840938600875347970,2017-03-12 20:22:40 IST,2017-03-12,20:22:40,+0530,112872946,biostocks,Bio Stocks™,,$GILD - Resisting the Allure of Gilead  https://t.co/JRXsQOLmB3 #biotech,en,[],['http://www.barrons.com/articles/resisting-the-allure-of-gilead-1489210516'],[],1,6,5,['biotech'],['gild'],https://twitter.com/BioStocks/status/840938600875347970,False,,0,,,,,,,,[],,,,
830409190451576832,830409190451576832,2017-02-11 19:02:33 IST,2017-02-11,19:02:33,+0530,244248703,jlyonsfundmgmt,Dana Lyons,,Gilead Sciences Testing (Breaking?) Multi-Decade Up Trendline $GILD  https://t.co/HZ8B56nqCG,en,[],[],['https://pbs.twimg.com/media/C4Y0wWaVYAEUWER.jpg'],2,7,9,[],['gild'],https://twitter.com/JLyonsFundMgmt/status/830409190451576832,False,,1,https://pbs.twimg.com/media/C4Y0wWaVYAEUWER.jpg,,,,,,,[],,,,
829767176651366400,829767176651366400,2017-02-10 00:31:25 IST,2017-02-10,00:31:25,+0530,14210851,moiselevi,Moise Levi,,"$GILD Gilead Sciences Inc. Don't buy a falling knive, but that cheap? PE : 6 with amazing ROE ! Put it on your watch list, not buying yet  https://t.co/LIhQIcD24i",en,[],[],['https://pbs.twimg.com/media/C4PsZTmWcAI4tPq.jpg'],0,1,7,[],['gild'],https://twitter.com/moiselevi/status/829767176651366400,False,,1,https://pbs.twimg.com/media/C4PsZTmWcAI4tPq.jpg,,,,,,,[],,,,
829323212261560320,829323212261560320,2017-02-08 19:07:16 IST,2017-02-08,19:07:16,+0530,244248703,jlyonsfundmgmt,Dana Lyons,,Gilead Sciences Testing (Breaking?) Multi-Decade Up Trendline $GILD  https://t.co/vdTRGNPx3H,en,[],[],['https://pbs.twimg.com/media/C4JZDeUUMAAJ2K9.jpg'],0,8,12,[],['gild'],https://twitter.com/JLyonsFundMgmt/status/829323212261560320,False,,1,https://pbs.twimg.com/media/C4JZDeUUMAAJ2K9.jpg,,,,,,,[],,,,
828995653988655105,828995653988655105,2017-02-07 21:25:40 IST,2017-02-07,21:25:40,+0530,466333756,seeitmarket,See It Market,,Gilead compressing into earnings.  Testing the 50 DMA from below.  Options pricing in a 3 dollar move.  $GILD $IBB  https://t.co/3IJ4ddxqce,en,[],[],['https://pbs.twimg.com/media/C4EvJu2WYAEvwe7.jpg'],0,3,5,[],"['gild', 'ibb']",https://twitter.com/seeitmarket/status/828995653988655105,False,,1,https://pbs.twimg.com/media/C4EvJu2WYAEvwe7.jpg,,,,,,,[],,,,
826346497566507008,826346497566507008,2017-01-31 13:58:52 IST,2017-01-31,13:58:52,+0530,2301944706,r4inb0w_,R4inb0w,,GENFIT : On continue de parler d'une cible potentielle bon marché pour Gilead $GILD $GNFT  https://t.co/jOe8iFXg17,fr,[],['http://bit.ly/2jxQbXT'],[],0,19,17,[],"['gild', 'gnft']",https://twitter.com/R4inb0w_/status/826346497566507008,False,,0,,,,,,,,[],,,,
821760974306873345,821760974306873345,2017-01-18 22:17:38 IST,2017-01-18,22:17:38,+0530,1469603575,qtrresearch,Quoth the Raven,,"*Hearing Gilead, Pfizer CEOs Currently Meeting at Davos, Traders Speculating M&amp;A Talks $PFE $GILD",en,[],[],[],1,12,6,[],"['pfe', 'gild']",https://twitter.com/QTRResearch/status/821760974306873345,False,,0,,,,,,,,[],,,,
818820182143631364,818820182143631364,2017-01-10 19:31:59 IST,2017-01-10,19:31:59,+0530,2334614718,openoutcrier,Open Outcrier,,TY to everyone who pointed out $GIL is Gildan &amp; $GILD is Gilead. No shit.  Exel's autofill isn't as smart as it thinks. (Sorry for yelling),en,[],[],[],2,0,8,[],"['gil', 'gild']",https://twitter.com/OpenOutcrier/status/818820182143631364,False,,0,,,,,,,,[],,,,
817381447820517378,817381447820517378,2017-01-06 20:14:58 IST,2017-01-06,20:14:58,+0530,1469603575,qtrresearch,Quoth the Raven,,*Hearing Carl Icahn Considering Activist Stake in Gilead $GILD,en,[],[],[],2,3,8,[],['gild'],https://twitter.com/QTRResearch/status/817381447820517378,False,,0,,,,,,,,[],,,,
816828623424548864,816828623424548864,2017-01-05 07:38:14 IST,2017-01-05,07:38:14,+0530,756650329924636672,relativitycap,RelativityCap,,"Could the bottom in Gilead $GILD be in place?  Presented w/ Fundamental, Options, Technical Snapshots  https://t.co/xW2ThbjKlY",en,[],[],"['https://pbs.twimg.com/media/C1X1SPrWQAAFMQB.jpg', 'https://pbs.twimg.com/media/C1X1SO4WIAAVWuU.jpg', 'https://pbs.twimg.com/media/C1X1SO7WQAAz4_r.jpg']",1,8,25,[],['gild'],https://twitter.com/RelativityCap/status/816828623424548864,False,,1,https://pbs.twimg.com/media/C1X1SPrWQAAFMQB.jpg,,,,,,,[],,,,
809538053253562368,809538053253562368,2016-12-16 04:48:07 IST,2016-12-16,04:48:07,+0530,13171622,pharmalot,pharmalot,,Gilead ordered to pay $2.54 billion to Merck for infringing hepatitis C #patents..  https://t.co/Hv3GfGywKw #pharma $GILD $MRK #hepatitis,en,[],['https://www.statnews.com/pharmalot/2016/12/15/gilead-merck-hepatitis-c-patents/'],[],0,8,7,"['patents', 'pharma', 'hepatitis']","['gild', 'mrk']",https://twitter.com/pharmalot/status/809538053253562368,False,,0,,,,,,,,[],,,,
809510648380084224,809510648380084224,2016-12-16 02:59:13 IST,2016-12-16,02:59:13,+0530,19717430,zbiotech,zach,,*GILEAD TOLD TO PAY MERCK $2.54 BILLION IN HEPATITIS C ROYALTIES $GILD $MRK,en,[],[],[],1,17,11,[],"['gild', 'mrk']",https://twitter.com/zbiotech/status/809510648380084224,False,,0,,,,,,,,[],,,,
799334684333395968,799334684333395968,2016-11-18 01:03:34 IST,2016-11-18,01:03:34,+0530,13171622,pharmalot,pharmalot,,How much longer will Gilead wait to buy its way out of the doldrums? read what the wags say  https://t.co/K23b34u6VG #pharma $GILD #hepatitis,en,[],['https://www.statnews.com/pharmalot/2016/11/17/gilead-hepatitis-clinical-trials/'],[],0,7,6,"['pharma', 'hepatitis']",['gild'],https://twitter.com/pharmalot/status/799334684333395968,False,,0,,,,,,,,[],,,,
799034523107422210,799034523107422210,2016-11-17 05:10:50 IST,2016-11-17,05:10:50,+0530,102094857,adamfeuerstein,Adam Feuerstein,,"I already used this hed for $GILD column:  ""Gilead Was Great Once but Is Now Awful and Depressing""  So, what now after momelotinib failure?",en,[],[],[],7,3,12,[],['gild'],https://twitter.com/adamfeuerstein/status/799034523107422210,False,,0,,,,,,,,[],,,,
798277028696965120,798277028696965120,2016-11-15 03:00:49 IST,2016-11-15,03:00:49,+0530,13171622,pharmalot,pharmalot,,Gilead's Harvoni hep C pill was biggest cost for Medicare and Medicaid last year - $9B!!  https://t.co/2ja8UvVHtS #pharma $GILD $ABBV $MRK,en,[],['https://www.statnews.com/pharmalot/2016/11/14/medicare-medicaid-gilead-hepatitis/'],[],1,46,20,['pharma'],"['gild', 'abbv', 'mrk']",https://twitter.com/pharmalot/status/798277028696965120,False,,0,,,,,,,,[],,,,
798142835413450752,798142835413450752,2016-11-14 18:07:35 IST,2016-11-14,18:07:35,+0530,818081647,analystwire,SIAnalystWire,,Stifel Starts Gilead Sciences $GILD at Buy  https://t.co/UX8XDh1SaX,en,[],['http://streetinsider.com/r/12238903'],[],0,3,6,[],['gild'],https://twitter.com/AnalystWire/status/798142835413450752,False,,0,,,,,,,,[],,,,
796776282352656386,796776282352656386,2016-11-10 23:37:23 IST,2016-11-10,23:37:23,+0530,545618159,wrigleytom,Tom Wrigley,,$GILD U.S. Food &amp; Drug Admin Approves Gilead's Vemlidy(R) (Tenofovir Alafenamide) for the Treatment of Chronic Hepatitis B Virus Infection,en,[],[],[],0,5,5,[],['gild'],https://twitter.com/WrigleyTom/status/796776282352656386,False,,0,,,,,,,,[],,,,
794276999720239105,794276999720239105,2016-11-04 02:06:08 IST,2016-11-04,02:06:08,+0530,758782075260510209,gaspareciviero,Gaspare Civiero,,"$GILD Gilead Sciences: #stock today &lt; $72,00.  #investing Survey:",en,[],[],[],0,1,5,"['stock', 'investing']",['gild'],https://twitter.com/GaspareCiviero/status/794276999720239105,False,,0,,,,,,,,[],,,,
793803853447725060,793803853447725060,2016-11-02 18:46:01 IST,2016-11-02,18:46:01,+0530,15281391,thestreet,TheStreet,,What happened to the once great Gilead?  https://t.co/Ic1LRzuUeW $GILD  https://t.co/OpMzj4iZVF,en,[],['http://trib.al/h05zrdD'],['https://pbs.twimg.com/media/CwQoZZLWEAEmHrw.jpg'],0,1,3,[],['gild'],https://twitter.com/TheStreet/status/793803853447725060,False,,1,https://pbs.twimg.com/media/CwQoZZLWEAEmHrw.jpg,,,,,,,[],,,,
793551185705701377,793551185705701377,2016-11-02 02:02:00 IST,2016-11-02,02:02:00,+0530,19717430,zbiotech,zach,,"*GILEAD: 119,000 HCV PATIENT STARTS IN 3Q16 VS 151,000 IN 3Q15 $GILD",en,[],[],[],0,1,5,[],['gild'],https://twitter.com/zbiotech/status/793551185705701377,False,,0,,,,,,,,[],,,,
793543467871965189,793543467871965189,2016-11-02 01:31:20 IST,2016-11-02,01:31:20,+0530,102754598,johncendpts,John Carroll,,Fast biotech: Gilead hands $200M to computational wiz Nimbus as it speeds into PhII NASH trial $GILD  https://t.co/BB7GGEhoUr,en,[],['https://endpts.com/fast-biotech-gilead-hands-200m-to-computational-wiz-nimbus-as-it-speeds-into-phii-nash-trial/'],[],0,8,9,[],['gild'],https://twitter.com/JohnCendpts/status/793543467871965189,False,,0,,,,,,,,[],,,,
789177491952771072,789177491952771072,2016-10-21 00:22:30 IST,2016-10-21,00:22:30,+0530,102754598,johncendpts,John Carroll,,Gilead needs a big R&amp;D hit. But claims on NASH fall well short of that $GILD  https://t.co/6q0Jy6IaV8,en,[],['http://endpts.com/gilead-needs-a-big-rd-hit-but-claims-on-nash-fall-well-short-of-that/'],[],1,10,6,[],['gild'],https://twitter.com/JohnCendpts/status/789177491952771072,False,,0,,,,,,,,[],,,,
787652977800601604,787652977800601604,2016-10-16 19:24:38 IST,2016-10-16,19:24:38,+0530,466333756,seeitmarket,See It Market,,Gilead Sciences Stock Analysis: Fundamentals Meet Technicals -  https://t.co/k7q8yO7qGq  blog by @FZucchi $GILD,en,"[{'screen_name': 'fzucchi', 'name': 'fzucchi', 'id': '17583317'}]",['http://www.seeitmarket.com/gilead-sciences-gild-fundamentals-technicals-investing-16147/'],[],1,6,7,[],['gild'],https://twitter.com/seeitmarket/status/787652977800601604,False,,0,,,,,,,,[],,,,
786302825068306432,786302825068306432,2016-10-13 01:59:36 IST,2016-10-13,01:59:36,+0530,466333756,seeitmarket,See It Market,,"New Blog - ""Gilead Sciences: Weighing The Fundamentals vs Technicals""  https://t.co/k7q8yO7qGq  by @FZucchi  $GILD  https://t.co/NGGcijxgew",en,"[{'screen_name': 'fzucchi', 'name': 'fzucchi', 'id': '17583317'}]",['http://www.seeitmarket.com/gilead-sciences-gild-fundamentals-technicals-investing-16147/'],['https://pbs.twimg.com/media/CumCMtBVIAAAKvx.jpg'],0,6,9,[],['gild'],https://twitter.com/seeitmarket/status/786302825068306432,False,,1,https://pbs.twimg.com/media/CumCMtBVIAAAKvx.jpg,,,,,,,[],,,,
785883934261252096,785883934261252096,2016-10-11 22:15:05 IST,2016-10-11,22:15:05,+0530,407221784,franklin19788,franklin Brown,,Jeffrey Sachs @JeffDSachs really went after Gilead $GILD for overpricing of its Hepatitis C drug Sovaldi #morningjoe  https://t.co/dNlYnFt36k,en,"[{'screen_name': 'jeffdsachs', 'name': 'jeffrey d. sachs', 'id': '116763916'}]",['http://www.msnbc.com/morning-joe/watch/why-government-can-t-negotiate-with-big-pharma-783346755816'],[],1,12,13,['morningjoe'],['gild'],https://twitter.com/franklin19788/status/785883934261252096,False,,0,,,,,,,,[],,,,
780776143544803328,780776143544803328,2016-09-27 19:58:33 IST,2016-09-27,19:58:33,+0530,15563814,loftus,Peter Loftus,,"Goldman ranks drug companies' reliance on pricing: Horizon, Jazz at high end; Lilly, Celgene, Gilead low end $HZNP $JAZZ $LLY $CELG $GILD  https://t.co/bYy5SNMvfv",en,[],[],['https://pbs.twimg.com/media/CtXfSUeVUAE9XCg.jpg'],2,59,64,[],"['hznp', 'jazz', 'lly', 'celg', 'gild']",https://twitter.com/Loftus/status/780776143544803328,False,,1,https://pbs.twimg.com/media/CtXfSUeVUAE9XCg.jpg,,,,,,,[],,,,
780762796019646464,780762796019646464,2016-09-27 19:05:31 IST,2016-09-27,19:05:31,+0530,102754598,johncendpts,John Carroll,,This was fun -- Porges: Gilead’s hep C bash is winding down and it doesn’t have a cure for the hangover $GILD - 1.5%  https://t.co/Mw776VcGJP,en,[],['http://endpts.com/porges-gileads-hep-c-bash-is-winding-down-and-it-doesnt-have-a-cure-for-the-hangover/'],[],0,6,6,[],['gild'],https://twitter.com/JohnCendpts/status/780762796019646464,False,,0,,,,,,,,[],,,,
778967476394684416,778967476394684416,2016-09-22 20:11:33 IST,2016-09-22,20:11:33,+0530,112872946,biostocks,Bio Stocks™,,$GILD - Gilead’s NASH program a “hidden asset.” - Gabelli  https://t.co/beBobJ2aFY $TBRA $ICPT,en,[],['http://blogs.barrons.com/stockstowatchtoday/2016/09/22/gilead-sciences-a-hidden-asset/'],[],1,3,6,[],"['gild', 'tbra', 'icpt']",https://twitter.com/BioStocks/status/778967476394684416,False,,0,,,,,,,,[],,,,
776804499541389312,776804499541389312,2016-09-16 20:56:39 IST,2016-09-16,20:56:39,+0530,2400426024,nodramafacts,NoDramaFacts,,$ARWR $GILD Gilead gearing up for acquisitions.  ARC520 next Sovaldi type blockbuster?  https://t.co/sGrcn0IpaD,en,[],[],['https://pbs.twimg.com/media/CsfDhXSVIAAquyE.jpg'],0,3,10,[],"['arwr', 'gild']",https://twitter.com/NoDramaFacts/status/776804499541389312,False,,1,https://pbs.twimg.com/media/CsfDhXSVIAAquyE.jpg,,,,,,,[],,,,
776802753339285504,776802753339285504,2016-09-16 20:49:43 IST,2016-09-16,20:49:43,+0530,84402174,street_insider,Streetinsider.com,,Language in Debt Offering Suggests Gilead's $GILD M&amp;A Team is Ready to Pounce - Jefferies  https://t.co/DqClOiwMBR,en,[],['http://www.streetinsider.com/Analyst+Comments/Language+in+Debt+Offering+Suggests+Gileads+%28GILD%29+M%26A+Team+is+Ready+to+Pounce+-+Jefferies/12039648.html'],[],1,5,6,[],['gild'],https://twitter.com/Street_Insider/status/776802753339285504,False,,0,,,,,,,,[],,,,
776476702591610880,776476702591610880,2016-09-15 23:14:06 IST,2016-09-15,23:14:06,+0530,15281391,thestreet,TheStreet,,"Gilead's pipeline, maligned by investors, still packed with 4Q clinical trial readouts  https://t.co/udEvaO6THZ $GILD  https://t.co/rYgpemkyAF",en,[],['http://trib.al/hutFPV7'],['https://pbs.twimg.com/media/CsaZceiWAAEeCVR.jpg'],0,2,5,[],['gild'],https://twitter.com/TheStreet/status/776476702591610880,False,,1,https://pbs.twimg.com/media/CsaZceiWAAEeCVR.jpg,,,,,,,[],,,,
775436972714328064,775436972714328064,2016-09-13 02:22:35 IST,2016-09-13,02:22:35,+0530,3426014292,semodough,dough,,"$GILD Gilead: The Phase I/II trial (NCT02343939) of entospletinib, Gilead's Syk inhibitor, in subjects with AML increased size from 120 -205",en,[],[],[],0,2,6,[],['gild'],https://twitter.com/semodough/status/775436972714328064,False,,0,,,,,,,,[],,,,
774190807117078528,774190807117078528,2016-09-09 15:50:46 IST,2016-09-09,15:50:46,+0530,32450040,evaluatevantage,Evaluate Vantage,,Vantage Snippet - Parp for the course for Gilead? $GILD  https://t.co/dQIBei9vgY,en,[],[],['https://pbs.twimg.com/media/Cr55wzGWYAAlUIs.jpg'],1,3,7,[],['gild'],https://twitter.com/evaluatevantage/status/774190807117078528,False,,1,https://pbs.twimg.com/media/Cr55wzGWYAAlUIs.jpg,,,,,,,[],,,,
773356388848373760,773356388848373760,2016-09-07 08:35:06 IST,2016-09-07,08:35:06,+0530,15281391,thestreet,TheStreet,,"Gilead should be manufacturing mergers too, says Jim Cramer:  https://t.co/9jVu03hAbn $GILD  https://t.co/Fctj2Y9rgw",en,[],['http://trib.al/CxCSZoZ'],['https://pbs.twimg.com/media/CruDiViXgAI2EWU.jpg'],0,5,7,[],['gild'],https://twitter.com/TheStreet/status/773356388848373760,False,,1,https://pbs.twimg.com/media/CruDiViXgAI2EWU.jpg,,,,,,,[],,,,
773187019904282624,773187019904282624,2016-09-06 21:22:05 IST,2016-09-06,21:22:05,+0530,15281391,thestreet,TheStreet,,"Gilead should be manufacturing mergers too, says Jim Cramer:  https://t.co/Nh0LFpv0sW $GILD  https://t.co/rt0VygAurW",en,[],['http://trib.al/4Nq31QE'],['https://pbs.twimg.com/media/CrrpfxqXgAAysGc.jpg'],0,5,8,[],['gild'],https://twitter.com/TheStreet/status/773187019904282624,False,,1,https://pbs.twimg.com/media/CrrpfxqXgAAysGc.jpg,,,,,,,[],,,,
771030869670699008,771030869670699008,2016-08-31 22:34:19 IST,2016-08-31,22:34:19,+0530,13171622,pharmalot,pharmalot,,University of Minnesota sues Gilead for infringing on hepatitis C patents.. read suit &amp; exhibits here.  https://t.co/LM0z3J90ut #pharma $GILD,en,[],['https://www.statnews.com/pharmalot/2016/08/31/university-minnesota-gilead-hepatitis-patents/'],[],1,13,11,['pharma'],['gild'],https://twitter.com/pharmalot/status/771030869670699008,False,,0,,,,,,,,[],,,,
768056601848737792,768056601848737792,2016-08-23 17:35:38 IST,2016-08-23,17:35:38,+0530,18294197,fiercebiotech,FierceBiotech,,"Gilead, Galapagos start PhIII of RA drug, 8 months after AbbVie began rival program:  https://t.co/VWOBpOwqdg  $GILD $GLPG $ABBV",en,[],['http://ow.ly/ZOnS303uTVP'],[],0,8,7,[],"['gild', 'glpg', 'abbv']",https://twitter.com/FierceBiotech/status/768056601848737792,False,,0,,,,,,,,[],,,,
767779139852046336,767779139852046336,2016-08-22 23:13:06 IST,2016-08-22,23:13:06,+0530,15281391,thestreet,TheStreet,,Gilead Sciences stock up on HIV drug approval:  https://t.co/mXEh4B8ght $GILD  https://t.co/0SJ2CNltqi,en,[],['http://trib.al/tMep45w'],['https://pbs.twimg.com/media/CqezDseXEAADz9s.jpg'],0,4,7,[],['gild'],https://twitter.com/TheStreet/status/767779139852046336,False,,1,https://pbs.twimg.com/media/CqezDseXEAADz9s.jpg,,,,,,,[],,,,
760914543132413953,760914543132413953,2016-08-04 00:35:38 IST,2016-08-04,00:35:38,+0530,57406450,henryechang,Henry E. Chang,,Gilead's response to @bmj_latest paper on the development of &amp; access to #HCV drugs→ https://t.co/ErWYOo2UkK #HepC #HepatitisC $GILD,en,"[{'screen_name': 'bmj_latest', 'name': 'the bmj', 'id': '16949344'}]",['http://ow.ly/awFp302Twzo'],[],0,14,6,"['hcv', 'hepc', 'hepatitisc']",['gild'],https://twitter.com/HenryEChang/status/760914543132413953,False,,0,,,,,,,,[],,,,
760863921511071748,760863921511071748,2016-08-03 21:14:29 IST,2016-08-03,21:14:29,+0530,13171622,pharmalot,pharmalot,,Gilead fires back at medical journal report critical of its pricing.. read the letter here..  https://t.co/u12BEFbBHk #pharma $GILD #BMJ,en,[],['https://www.statnews.com/pharmalot/2016/08/03/gilead-fires-back-report-pricing/'],[],1,6,6,"['pharma', 'bmj']",['gild'],https://twitter.com/pharmalot/status/760863921511071748,False,,0,,,,,,,,[],,,,
760134851961860096,760134851961860096,2016-08-01 20:57:25 IST,2016-08-01,20:57:25,+0530,262652488,vegastrader66,Vegastrader66,,$BMY $GILD  Gilead Spikes to High; Hearing Unconfirmed Market Chatter Co Talking With BMY Regarding Merger,en,[],[],[],0,5,5,[],"['bmy', 'gild']",https://twitter.com/Vegastrader66/status/760134851961860096,False,,0,,,,,,,,[],,,,
758030003015528448,758030003015528448,2016-07-27 01:33:30 IST,2016-07-27,01:33:30,+0530,13171622,pharmalot,pharmalot,,"As hep C sales decline, what does Gilead do for its next act? Here's what a few wags say:  https://t.co/YQCdstKb9c #pharma $GILD #hepatitis",en,[],['https://www.statnews.com/pharmalot/2016/07/26/hepatitis-wall-street-gilead/'],[],1,3,7,"['pharma', 'hepatitis']",['gild'],https://twitter.com/pharmalot/status/758030003015528448,False,,0,,,,,,,,[],,,,
750350162887741440,750350162887741440,2016-07-05 20:56:34 IST,2016-07-05,20:56:34,+0530,13171622,pharmalot,pharmalot,,Gilead price hikes on HIV drugs anger AIDS activists.. another pricing controversy?   https://t.co/sJcy4PzOBk #pharma #HIV #AIDS $GILD,en,[],['https://www.statnews.com/pharmalot/2016/07/05/gilead-hiv-aids-drug-prices/'],[],0,8,5,"['pharma', 'hiv', 'aids']",['gild'],https://twitter.com/pharmalot/status/750350162887741440,False,,0,,,,,,,,[],,,,
747807183392346116,747807183392346116,2016-06-28 20:31:40 IST,2016-06-28,20:31:40,+0530,19717430,zbiotech,zach,,"*GILEAD CEO SAYS EPCLUSA LIST PRICE WILL BE $74,760 FOR 12 WEEKS $GILD",en,[],[],[],1,13,11,[],['gild'],https://twitter.com/zbiotech/status/747807183392346116,False,,0,,,,,,,,[],,,,
745948585720709120,745948585720709120,2016-06-23 17:26:16 IST,2016-06-23,17:26:16,+0530,545618159,wrigleytom,Tom Wrigley,,$GILD  European Commission Grants Marketing Authorization for Gilead’s Single Tablet Regimen Odefsey® ...   https://t.co/RWjjbA0nXt,en,[],['http://finance.yahoo.com/news/european-commission-grants-marketing-authorization-115300844.html?soc_src=mediacontentstory&soc_trk=tw'],[],0,3,7,[],['gild'],https://twitter.com/WrigleyTom/status/745948585720709120,False,,0,,,,,,,,[],,,,
742708120326148096,742708120326148096,2016-06-14 18:49:49 IST,2016-06-14,18:49:49,+0530,19717430,zbiotech,zach,,"*GILEAD SAYS TWO EBOLA PATIENTS TREATED WITH GS-5734, BOTH CURED  long-term growth...solved $GILD",en,[],[],[],1,10,22,[],['gild'],https://twitter.com/zbiotech/status/742708120326148096,False,,0,,,,,,,,[],,,,
741277993939664901,741277993939664901,2016-06-10 20:07:00 IST,2016-06-10,20:07:00,+0530,19717430,zbiotech,zach,,*GILEAD: ’BACKBONE ASSET’ IN ONCOLOGY WOULD BE VERY ATTRACTIVE $GILD,en,[],[],[],1,2,5,[],['gild'],https://twitter.com/zbiotech/status/741277993939664901,False,,0,,,,,,,,[],,,,
741122074580783104,741122074580783104,2016-06-10 09:47:26 IST,2016-06-10,09:47:26,+0530,57406450,henryechang,Henry E. Chang,,Gilead's #HCV drug discovery effort ended ~2 years ago; shifted resources to #HBV drug development says $GILD's CSO.  https://t.co/m602fR5uiX,en,[],[],['https://pbs.twimg.com/media/Ckj-mNjXIAANzxa.jpg'],0,9,8,"['hcv', 'hbv']",['gild'],https://twitter.com/HenryEChang/status/741122074580783104,False,,1,https://pbs.twimg.com/media/Ckj-mNjXIAANzxa.jpg,,,,,,,[],,,,
740298466220347393,740298466220347393,2016-06-08 03:14:43 IST,2016-06-08,03:14:43,+0530,15563814,loftus,Peter Loftus,,"Judge sides with Gilead against Merck in hepatitis C drug patent dispute, blasts Merck conduct:  https://t.co/cqkibrdTwO via @WSJ $MRK $GILD",en,"[{'screen_name': 'wsj', 'name': 'the wall street journal', 'id': '3108351'}]",['http://on.wsj.com/1tfCz9j'],[],0,14,4,[],"['mrk', 'gild']",https://twitter.com/Loftus/status/740298466220347393,False,,0,,,,,,,,[],,,,
728972323924156416,728972323924156416,2016-05-07 21:08:40 IST,2016-05-07,21:08:40,+0530,1469603575,qtrresearch,Quoth the Raven,,Gilead $GILD Chief Has $21 Billion in Cash and an Itch to Do a Deal  https://t.co/jGrLfeRDGR #biotech,en,[],['http://bloom.bg/1YcPD8H'],[],1,2,5,['biotech'],['gild'],https://twitter.com/QTRResearch/status/728972323924156416,False,,0,,,,,,,,[],,,,
727243246783574017,727243246783574017,2016-05-03 02:37:56 IST,2016-05-03,02:37:56,+0530,15563814,loftus,Peter Loftus,,Judge allows more evidence in HepC patent dispute after Gilead says ex-Merck attorney lied:  https://t.co/ANVkgNS1PR via @WSJ $MRK $GILD,en,"[{'screen_name': 'wsj', 'name': 'the wall street journal', 'id': '3108351'}]",['http://on.wsj.com/1Ocfvvx'],[],1,13,9,[],"['mrk', 'gild']",https://twitter.com/Loftus/status/727243246783574017,False,,0,,,,,,,,[],,,,
716971251823194113,716971251823194113,2016-04-04 18:20:41 IST,2016-04-04,18:20:41,+0530,18294197,fiercebiotech,FierceBiotech,,Gilead bags early-stage NASH drug in $1.2B Nimbus deal:  https://t.co/ife34ADmCd via @JohnCFierce $GILD,en,"[{'screen_name': 'johncfierce', 'name': 'phyllis m. yang', 'id': '739133634532106240'}]",['http://ow.ly/10gd6q'],[],0,6,6,[],['gild'],https://twitter.com/FierceBiotech/status/716971251823194113,False,,0,,,,,,,,[],,,,
716970444914470912,716970444914470912,2016-04-04 18:17:29 IST,2016-04-04,18:17:29,+0530,102754598,johncendpts,John Carroll,,Biotech valuations don't look to be declining much --  Gilead bags early-stage NASH drug in $1.2B Nimbus deal $GILD  https://t.co/4Y61yf0PR8,en,[],['http://www.fiercebiotech.com/story/gilead-bags-early-stage-nash-drug-12b-nimbus-deal/2016-04-04'],[],1,9,11,[],['gild'],https://twitter.com/JohnCendpts/status/716970444914470912,False,,0,,,,,,,,[],,,,
714498756037767169,714498756037767169,2016-03-28 22:35:52 IST,2016-03-28,22:35:52,+0530,18294275,fiercepharma,FiercePharma,,Merck's $200M damages in Gilead hep C case falls far short of expectations  https://t.co/cZFoF4tjQi $MRK $GILD #pharma by @TracyStaton,en,"[{'screen_name': 'tracystaton', 'name': 'tracy staton', 'id': '27012894'}]",['http://www.fiercepharma.com/story/mercks-200m-damages-gilead-hep-c-case-falls-far-short-expectations/2016-03-28'],[],2,6,5,['pharma'],"['mrk', 'gild']",https://twitter.com/FiercePharma/status/714498756037767169,False,,0,,,,,,,,[],,,,
714432379159318528,714432379159318528,2016-03-28 18:12:07 IST,2016-03-28,18:12:07,+0530,2334614718,openoutcrier,Open Outcrier,,$GILD (+1.0% pre) IMS Script Data Shows Gilead Sciences Maintaining HCV Lead - Leerink    https://t.co/JlyDLCNinz,en,[],['http://ooc.bz/l/1455'],[],0,4,8,[],['gild'],https://twitter.com/OpenOutcrier/status/714432379159318528,False,,0,,,,,,,,[],,,,
713166937522475010,712388356492169216,2016-03-25 06:23:42 IST,2016-03-25,06:23:42,+0530,632341632,andybiotech,Andy Biotech,,$GILD $MRK @TradeTexasBig Think both sides will appeal. Gilead is not willing to pay these patent troll a damn penny  https://t.co/irwhkmTX1u,en,"[{'screen_name': 'tradetexasbig', 'name': 'millionadaytxtrader', 'id': '612135517'}]",['https://twitter.com/ScripMandy/status/713161601424044033'],[],3,2,15,[],"['gild', 'mrk']",https://twitter.com/AndyBiotech/status/713166937522475010,False,https://twitter.com/ScripMandy/status/713161601424044033,0,,,,,,,,[],,,,
713160173003472896,712388356492169216,2016-03-25 05:56:49 IST,2016-03-25,05:56:49,+0530,632341632,andybiotech,Andy Biotech,,"$GILD vs $MRK #HCV patent case: Jury ordered Gilead to pay Merck $200M in damages(&lt;$40M for $IONS), far less than the $2B Merck had demanded",en,[],[],[],5,12,18,['hcv'],"['gild', 'mrk', 'ions']",https://twitter.com/AndyBiotech/status/713160173003472896,False,,0,,,,,,,,[],,,,
712406690151399425,712406690151399425,2016-03-23 04:02:45 IST,2016-03-23,04:02:45,+0530,15563814,loftus,Peter Loftus,,Merck Gets Win Over Gilead in Hepatitis C Drug Patent Dispute       https://t.co/HFjICoTMZ2 via @WSJ $MRK $GILD,en,"[{'screen_name': 'wsj', 'name': 'the wall street journal', 'id': '3108351'}]",['http://on.wsj.com/1VBINdI'],[],1,9,5,[],"['mrk', 'gild']",https://twitter.com/Loftus/status/712406690151399425,False,,0,,,,,,,,[],,,,
710570592269934592,710570592269934592,2016-03-18 02:26:45 IST,2016-03-18,02:26:45,+0530,13171622,pharmalot,pharmalot,,Gilead strategy to develop cancer drugs in doubt after setbacks.. halted trials &amp; a key exec leaves  https://t.co/fzeHOvfk3c #pharma $GILD,en,[],['http://www.statnews.com/pharmalot/2016/03/17/gilead-cancer-hepatitis-c/'],[],0,4,6,['pharma'],['gild'],https://twitter.com/pharmalot/status/710570592269934592,False,,0,,,,,,,,[],,,,
709796408237367296,709796408237367296,2016-03-15 23:10:25 IST,2016-03-15,23:10:25,+0530,2301944706,r4inb0w_,R4inb0w,,Barclays HC : Gilead is looking for opportunities... The sector may rebound faster than we think (Milligan) $GILD  https://t.co/8uA0oYEu3p,en,[],[],['https://pbs.twimg.com/media/Cdm0EksW8AATDh2.jpg'],0,15,12,[],['gild'],https://twitter.com/R4inb0w_/status/709796408237367296,False,,1,https://pbs.twimg.com/media/Cdm0EksW8AATDh2.jpg,,,,,,,[],,,,
697436024834760704,697436024834760704,2016-02-10 20:34:40 IST,2016-02-10,20:34:40,+0530,2301944706,r4inb0w_,R4inb0w,,"BIO CEO &amp; Investor Conference 02/09. Gilead/Milligan ""Open to new deals in NASH and other areas"" $GILD $ICPT $GNFT  https://t.co/ohAykEsuZC",en,[],[],['https://pbs.twimg.com/media/Ca3KXjaW0AEqu-H.jpg'],2,29,13,[],"['gild', 'icpt', 'gnft']",https://twitter.com/R4inb0w_/status/697436024834760704,False,,1,https://pbs.twimg.com/media/Ca3KXjaW0AEqu-H.jpg,,,,,,,[],,,,
694926852679315462,694926852679315462,2016-02-03 22:24:07 IST,2016-02-03,22:24:07,+0530,84402174,street_insider,Streetinsider.com,,Gilead Sciences $GILD Potential M&amp;A In Focus  https://t.co/kcEYdpDQr9,en,[],['http://stks.co/d3FME'],[],0,3,4,[],['gild'],https://twitter.com/Street_Insider/status/694926852679315462,False,,0,,,,,,,,[],,,,
694822469585256448,694822469585256448,2016-02-03 15:29:20 IST,2016-02-03,15:29:20,+0530,2301944706,r4inb0w_,R4inb0w,,"GILEAD continues its R&amp;D efforts in NASH, Milligan said. FXR agonist and a ""shopping list"" in mind $GILD $GNFT $ICPT  https://t.co/sZKWAj1cQg",en,[],[],['https://pbs.twimg.com/media/CaSBWnlXEAA4j8n.jpg'],0,20,14,[],"['gild', 'gnft', 'icpt']",https://twitter.com/R4inb0w_/status/694822469585256448,False,,1,https://pbs.twimg.com/media/CaSBWnlXEAA4j8n.jpg,,,,,,,[],,,,
694629386813882368,694629386813882368,2016-02-03 02:42:06 IST,2016-02-03,02:42:06,+0530,15563814,loftus,Peter Loftus,,Gilead's 2-year haul from HepC drugs Harvoni and Sovaldi: $31.55 billion. Price paid to acquire Pharmasset: $11.1 billion. $GILD,en,[],[],[],2,29,24,[],['gild'],https://twitter.com/Loftus/status/694629386813882368,False,,0,,,,,,,,[],,,,
694626542710714369,694626542710714369,2016-02-03 02:30:47 IST,2016-02-03,02:30:47,+0530,44060322,benzinga,Benzinga,,"Gilead Sciences Reports Q4 EPS $3.32 Vs Est $2.99, Sales $8.51B Vs Est $8.13B $GILD",en,[],[],[],0,10,9,[],['gild'],https://twitter.com/Benzinga/status/694626542710714369,False,,0,,,,,,,,[],,,,
694287321903009793,694287321903009793,2016-02-02 04:02:51 IST,2016-02-02,04:02:51,+0530,13171622,pharmalot,pharmalot,,Gilead is accused of manipulating patents to dominate HIV drug market.. read lawsuit here..  https://t.co/hLi38XBIT6 #pharma $GILD #HIV #AIDS,en,[],['http://www.statnews.com/pharmalot/2016/02/01/gilead-patents-hiv/'],[],2,12,9,"['pharma', 'hiv', 'aids']",['gild'],https://twitter.com/pharmalot/status/694287321903009793,False,,0,,,,,,,,[],,,,
694146364452769792,694146364452769792,2016-02-01 18:42:44 IST,2016-02-01,18:42:44,+0530,879161563,cmichaelgibson,C. Michael Gibson MD,,Merck ($MRK) Takes on Gilead ($GILD) With 32% Lower Hepatitis C Drug Price - TheStreet  https://t.co/jEXZDLj9vl,en,[],['http://www.thestreet.com/story/13440730/1/merck-takes-on-gilead-with-sharply-lower-hepatitis-c-drug-price.html'],[],0,4,5,[],[],https://twitter.com/CMichaelGibson/status/694146364452769792,False,,0,,,,,,,,[],,,,
693113878482395136,693113878482395136,2016-01-29 22:20:00 IST,2016-01-29,22:20:00,+0530,19546277,yahoofinance,Yahoo Finance,,Stocks to watch: PlayStation boosts Sony's sales; Amazon sinks on earnings; Gilead's drug-price war  https://t.co/FndCqrCOAI $SNE $AMZN $GILD,en,[],['http://yhoo.it/1m1hnzk'],[],1,9,6,[],"['sne', 'amzn', 'gild']",https://twitter.com/YahooFinance/status/693113878482395136,False,,0,,,,,,,,[],,,,
693093477664571392,693093477664571392,2016-01-29 20:58:56 IST,2016-01-29,20:58:56,+0530,61342056,optionshawk,Joe Kunkle,,"Gilead $GILD trades the February $89/$93/$97 call fly 25,000X50,000 at $0.40 debit",en,[],[],[],0,6,5,[],['gild'],https://twitter.com/OptionsHawk/status/693093477664571392,False,,0,,,,,,,,[],,,,
692844354155597825,692844354155597825,2016-01-29 04:29:01 IST,2016-01-29,04:29:01,+0530,102754598,johncendpts,John Carroll,,Merck gets FDA OK to go toe-to-toe with Gilead's hep C market goliath $MRK $GILD  https://t.co/heNHOvCHaN,en,[],['http://www.fiercebiotech.com/story/merck-gets-fda-ok-go-toe-toe-gileads-hep-c-market-goliath/2016-01-28'],[],0,4,4,[],"['mrk', 'gild']",https://twitter.com/JohnCendpts/status/692844354155597825,False,,0,,,,,,,,[],,,,
691632825729171456,691632825729171456,2016-01-25 20:14:50 IST,2016-01-25,20:14:50,+0530,2301944706,r4inb0w_,R4inb0w,,GENFIT : Portzamparc (Arnaud Guerin) Cites Speculation of Possible M&amp;A (Bloomberg) Gilead ?? $GNFT $GILD #NASH  https://t.co/Q2VzZxFYJX,en,[],[],['https://pbs.twimg.com/media/CZksX8DWwAAKICN.png'],2,52,23,['nash'],"['gnft', 'gild']",https://twitter.com/R4inb0w_/status/691632825729171456,False,,1,https://pbs.twimg.com/media/CZksX8DWwAAKICN.png,,,,,,,[],,,,
684443532531089408,684443532531089408,2016-01-06 00:07:09 IST,2016-01-06,00:07:09,+0530,18294275,fiercepharma,FiercePharma,,Gilead wins speedy FDA review for latest hep C combo  https://t.co/o8eOFQNV87 $GILD #pharma by @EmilyWFierce,en,"[{'screen_name': 'emilywfierce', 'name': 'emily wasserman', 'id': '2279548740'}]",['http://www.fiercepharma.com/story/gilead-wins-speedy-fda-review-latest-hep-c-combo/2016-01-05'],[],0,5,9,['pharma'],['gild'],https://twitter.com/FiercePharma/status/684443532531089408,False,,0,,,,,,,,[],,,,
684395224081248256,684395224081248256,2016-01-05 20:55:11 IST,2016-01-05,20:55:11,+0530,18294197,fiercebiotech,FierceBiotech,,Gilead lines up for a fast FDA OK with its next-gen hep C combo.  https://t.co/oK1aXlSjhG by @DamianFierce $GILD,en,[],['http://www.fiercebiotech.com/story/gilead-lines-fast-fda-ok-its-next-gen-hep-c-combo/2016-01-05'],[],0,3,6,[],['gild'],https://twitter.com/FierceBiotech/status/684395224081248256,False,,0,,,,,,,,[],,,,
684102703635501056,684102703635501056,2016-01-05 01:32:49 IST,2016-01-05,01:32:49,+0530,100024370,ophirgottlieb,Ophir Gottlieb,,$GILD It's time to buy Gilead. Period.,en,[],[],[],2,3,5,[],['gild'],https://twitter.com/OphirGottlieb/status/684102703635501056,False,,0,,,,,,,,[],,,,
675257153905696768,675257153905696768,2015-12-11 15:43:45 IST,2015-12-11,15:43:45,+0530,292876633,kristen_hallam,Kristen Hallam,,Great story by @RobertLangreth - How Gilead priced its $20 billion blockbuster  https://t.co/B4siDELp5G via @business $GILD,en,"[{'screen_name': 'robertlangreth', 'name': 'robert langreth', 'id': '81124540'}, {'screen_name': 'business', 'name': 'bloomberg', 'id': '34713362'}]",['http://bloom.bg/1RHnjtP'],[],0,7,8,[],['gild'],https://twitter.com/kristen_hallam/status/675257153905696768,False,,0,,,,,,,,[],,,,
671820944437026816,671820944437026816,2015-12-02 04:09:29 IST,2015-12-02,04:09:29,+0530,15563814,loftus,Peter Loftus,,Gilead exec email on Sovaldi pricing: 'Let’s not fold to advocacy pressure...whatever the headlines'  https://t.co/tzJSFnKjVD via @WSJ $GILD,en,"[{'screen_name': 'wsj', 'name': 'the wall street journal', 'id': '3108351'}]",['http://on.wsj.com/1NoR3tE'],[],1,20,9,[],['gild'],https://twitter.com/Loftus/status/671820944437026816,False,,0,,,,,,,,[],,,,
659379361754124292,659379361754124292,2015-10-28 20:11:05 IST,2015-10-28,20:11:05,+0530,386616537,tstbiotech,TheStreet Biotech,,Gilead Proves Again Why It's the Best Biotech Company on the Planet $GILD  https://t.co/59GRkQXw1D  https://t.co/nEqKDvB3Tf,en,[],['http://dlvr.it/CZh6Kw'],['https://pbs.twimg.com/media/CSaWCSNUEAACOc_.jpg'],1,8,6,[],['gild'],https://twitter.com/TSTbiotech/status/659379361754124292,False,,1,https://pbs.twimg.com/media/CSaWCSNUEAACOc_.jpg,,,,,,,[],,,,
654643993465233408,654643993465233408,2015-10-15 18:34:25 IST,2015-10-15,18:34:25,+0530,2279548740,emilywfierce,Emily Wasserman,,Advera: AbbVie's Viekira Pak riskier than Gilead's Harvoni for hep C:  http://t.co/TQtCPInHHg $ABBV $GILD #pharma,en,[],['http://www.fiercepharma.com/story/advera-abbvies-viekira-pak-riskier-gileads-harvoni-hep-c/2015-10-15'],[],0,4,3,['pharma'],"['abbv', 'gild']",https://twitter.com/EmilyWFierce/status/654643993465233408,False,,0,,,,,,,,[],,,,
650617427319885824,650617427319885824,2015-10-04 15:54:17 IST,2015-10-04,15:54:17,+0530,2796938558,cmlviz,Capital Market Laboratories,,$GILD Right Now: Gilead is Suddenly Impossible to Ignore  http://t.co/VbDvkdiPKE  http://t.co/OacMZgKYbM,en,[],['http://www.cmlviz.com/cmld3b/lite.php?ticker=gild&app=rc#story'],['https://pbs.twimg.com/media/CQd1GkCU8AA_iAN.jpg'],0,1,3,[],['gild'],https://twitter.com/CMLviz/status/650617427319885824,False,,1,https://pbs.twimg.com/media/CQd1GkCU8AA_iAN.jpg,,,,,,,[],,,,
638841176955731968,638841176955731968,2015-09-02 03:59:40 IST,2015-09-02,03:59:40,+0530,26775476,hedgefundclone,hedgefundclone,,"$GILD Gilead is just ridiculously cheap! P/E of 8, Price to Free Cash Flow of 9, and its a Buffett like wide moat stock with an ROE of 96!",en,[],[],[],1,2,12,[],['gild'],https://twitter.com/hedgefundclone/status/638841176955731968,False,,0,,,,,,,,[],,,,
634017583021199360,634017583021199360,2015-08-19 20:32:25 IST,2015-08-19,20:32:25,+0530,2772167606,smallcapbreak,Long Term Small Caps,,"A Review Of Gilead's Pipeline (Pt 1) GILD ABBV, ACHN, GBIM, ICPT and more  http://t.co/mlsMeAcsfM $crbp $srpt $cyan $biib $ontx $drna $cycc",in,[],['http://www.seekingalpha.com/article/3447806-a-review-of-gileads-pipeline-part-1'],[],0,2,15,[],"['crbp', 'srpt', 'cyan', 'biib', 'ontx', 'drna', 'cycc']",https://twitter.com/SmallCapBreak/status/634017583021199360,False,,0,,,,,,,,[],,,,
633478567251308544,633478567251308544,2015-08-18 08:50:34 IST,2015-08-18,08:50:34,+0530,21328656,ibdinvestors,Investors.com,,"Facebook, Gilead are among several big-cap tech and biotech stocks that are holding up well  http://t.co/hqIyOp0TSt $FB $GOOGL $GILD",en,[],['http://ow.ly/R1dEG'],[],1,7,11,[],"['fb', 'googl', 'gild']",https://twitter.com/IBDinvestors/status/633478567251308544,False,,0,,,,,,,,[],,,,
626129070015680512,626129070015680512,2015-07-29 02:06:17 IST,2015-07-29,02:06:17,+0530,26775476,hedgefundclone,hedgefundclone,,Gilead Sciences $GILD: ‘Appears to Be an Awesome Quarter’  http://t.co/osOQnTe7BH via @barons online,en,"[{'screen_name': 'barons', 'name': 'anthony chavez', 'id': '313108653'}]",['http://blogs.barrons.com/stockstowatchtoday/2015/07/28/gilead-sciences-big-beat-big-gain/'],[],0,1,11,[],['gild'],https://twitter.com/hedgefundclone/status/626129070015680512,False,,0,,,,,,,,[],,,,
626128539352367104,626128539352367104,2015-07-29 02:04:11 IST,2015-07-29,02:04:11,+0530,26775476,hedgefundclone,hedgefundclone,,"Gilead $GILD 2nd-quarter profit increases 32 pct, 2015 outlook raised  http://t.co/MuJsIKJX70 via @YahooFinance",en,"[{'screen_name': 'yahoofinance', 'name': 'yahoo finance', 'id': '19546277'}]",['http://finance.yahoo.com/news/gilead-2nd-quarter-profit-increases-202324212.html?soc_src=mediacontentstory&soc_trk=tw'],[],0,3,6,[],['gild'],https://twitter.com/hedgefundclone/status/626128539352367104,False,,0,,,,,,,,[],,,,
626125620615888896,626125620615888896,2015-07-29 01:52:35 IST,2015-07-29,01:52:35,+0530,386616537,tstbiotech,TheStreet Biotech,,"Gilead Q2 Earnings: KAPOW! BAM! BOOM! (Yes, That Good) $GILD  http://t.co/AGsEqco4hk  http://t.co/PswgjumcWu",en,[],['http://dlvr.it/BgSLxc'],['https://pbs.twimg.com/media/CLBx7yyVEAAhHZq.jpg'],1,14,6,[],['gild'],https://twitter.com/TSTbiotech/status/626125620615888896,False,,1,https://pbs.twimg.com/media/CLBx7yyVEAAhHZq.jpg,,,,,,,[],,,,
626119548224147456,626119548224147456,2015-07-29 01:28:27 IST,2015-07-29,01:28:27,+0530,37718217,thedomino,Dominic Chu,,After the bell earnings fireworks? Options market pricing in: Twitter $TWTR +/- 13% Gilead $GILD +/- 6% $YELP +/- 14% Panera $PNRA +/- 6%,en,[],[],[],1,6,10,[],"['twtr', 'gild', 'yelp', 'pnra']",https://twitter.com/TheDomino/status/626119548224147456,False,,0,,,,,,,,[],,,,
623895045087703041,623895045087703041,2015-07-22 22:09:04 IST,2015-07-22,22:09:04,+0530,18294275,fiercepharma,FiercePharma,,"Drugmakers like Gilead, Mylan and Novo--not Big Pharma--are job creators  http://t.co/8ynxsVk9uX $GILD $MYL $NVO #pharma by @EricPFierce",en,"[{'screen_name': 'ericpfierce', 'name': 'eric palmer', 'id': '479884627'}]",['http://www.fiercepharma.com/story/drugmakers-gilead-mylan-and-novo-not-big-pharma-are-job-creators/2015-07-22'],[],0,6,6,['pharma'],"['gild', 'myl', 'nvo']",https://twitter.com/FiercePharma/status/623895045087703041,False,,0,,,,,,,,[],,,,
623495412649959424,623495412649959424,2015-07-21 19:41:05 IST,2015-07-21,19:41:05,+0530,140912249,davidfaber,David Faber,,"Facebook market cap accretion is staggering, but I am more amazed that Gilead is now worth $7b more than mighty Merck. $GILD, $MRK, $FB",en,[],[],[],4,10,16,[],"['gild', 'mrk', 'fb']",https://twitter.com/davidfaber/status/623495412649959424,False,,0,,,,,,,,[],,,,
622018170640068608,622018170640068608,2015-07-17 17:51:03 IST,2015-07-17,17:51:03,+0530,13171622,pharmalot,pharmalot,,ICYMI: Gilead limits enrollment in its Hep C patient assistance program to pressure insurers..  http://t.co/gXYOyH2jOs #pharma $GILD,en,[],['http://blogs.wsj.com/pharmalot/2015/07/16/gilead-limits-enrollment-in-its-hep-c-patient-program-to-pressure-insurers/'],[],0,21,9,['pharma'],['gild'],https://twitter.com/pharmalot/status/622018170640068608,False,,0,,,,,,,,[],,,,
621143725352353792,621143725352353792,2015-07-15 07:56:19 IST,2015-07-15,07:56:19,+0530,61342056,optionshawk,Joe Kunkle,,Your move Gilead $GILD - opining on some of their potential targets  http://t.co/OH8qPzh5t3,en,[],[],['https://pbs.twimg.com/media/CJ6-65zUAAAT2QB.png'],10,35,86,[],['gild'],https://twitter.com/OptionsHawk/status/621143725352353792,False,,1,https://pbs.twimg.com/media/CJ6-65zUAAAT2QB.png,,,,,,,[],,,,
607554944359612416,607554944359612416,2015-06-07 19:59:21 IST,2015-06-07,19:59:21,+0530,475524030,wallstjesus,JE$US,,IBD: Weekend Watch List: Gilead nearing possible buy point in first-stage base  http://t.co/ZuMxKpXIHP $GILD,en,[],['http://ow.ly/NXTc8'],[],0,4,8,[],['gild'],https://twitter.com/WallStJesus/status/607554944359612416,False,,0,,,,,,,,[],,,,
607548882118176768,607548882118176768,2015-06-07 19:35:15 IST,2015-06-07,19:35:15,+0530,21328656,ibdinvestors,Investors.com,,Weekend Watch List: Gilead nearing possible buy point in first-stage base  http://t.co/ZICcieVu3Q $GILD,en,[],['http://ow.ly/NXTc8'],[],0,4,10,[],['gild'],https://twitter.com/IBDinvestors/status/607548882118176768,False,,0,,,,,,,,[],,,,
603940259861286913,603940259861286913,2015-05-28 20:35:53 IST,2015-05-28,20:35:53,+0530,102754598,johncendpts,John Carroll,,"Booming Gilead is opening new labs, planning fresh hires in R&amp;D blitz $GILD #biotech vs. #pharma  http://t.co/mmbALDL7QF",en,[],['http://www.fiercebiotech.com/story/booming-gilead-opening-new-labs-planning-fresh-hires-rd-blitz/2015-05-28'],[],2,6,8,"['biotech', 'pharma']",['gild'],https://twitter.com/JohnCendpts/status/603940259861286913,False,,0,,,,,,,,[],,,,
594011288889491457,594011288889491457,2015-05-01 11:01:42 IST,2015-05-01,11:01:42,+0530,471121755,pnani456,Ani Anirudhan,,$GILD Gilead CEO: “We are taking suggestions” on companies to buy - Fortune $IBB  http://t.co/gwi2tllAS1,en,[],['http://fortune.com/2015/04/30/gilead-acquisition-targets/?xid=yahoo_fortune'],[],2,8,6,[],"['gild', 'ibb']",https://twitter.com/pnani456/status/594011288889491457,False,,0,,,,,,,,[],,,,
591220034288152577,591220034288152577,2015-04-23 18:10:15 IST,2015-04-23,18:10:15,+0530,102754598,johncendpts,John Carroll,,The next-next gen thing: Merck and Gilead square off in battle of the next-next-gen hep C combos $MRK $GILD  http://t.co/zMlgiIoD4Q,en,[],['http://www.fiercebiotech.com/story/merck-and-gilead-square-battle-next-next-gen-hep-c-combos/2015-04-23'],[],1,3,7,[],"['mrk', 'gild']",https://twitter.com/JohnCendpts/status/591220034288152577,False,,0,,,,,,,,[],,,,
589696454484238336,589696454484238336,2015-04-19 13:16:05 IST,2015-04-19,13:16:05,+0530,2494896473,biotech2050,Biotech2050 💎✋,,"Since 01/01/14, $GILD initiated 71 clinical trials (market considers Gilead Science as not investing in pipeline!)  https://t.co/amln8FQJHT",en,[],['https://clinicaltrials.gov/ct2/results?term=&recr=&rslt=&type=&cond=&intr=&titles=&outc=&spons=&lead=gilead&id=&state1=&cntry1=&state2=&cntry2=&state3=&cntry3=&locn=&gndr=&rcv_s=01%2F01%2F2014&rcv_e=&lup_s=&lup_e='],[],0,3,5,[],['gild'],https://twitter.com/Biotech2050/status/589696454484238336,False,,0,,,,,,,,[],,,,
586601646056058880,586601646056058880,2015-04-11 00:18:25 IST,2015-04-11,00:18:25,+0530,26775476,hedgefundclone,hedgefundclone,,"Watch $GILD Gilead, Buffett Like Wide Moat Biotech Stock selling for only 9 times earnings and just broke out of a Huge Sideways Pattern!",en,[],[],[],5,6,8,[],['gild'],https://twitter.com/hedgefundclone/status/586601646056058880,False,,0,,,,,,,,[],,,,
586561263355822080,586561263355822080,2015-04-10 21:37:57 IST,2015-04-10,21:37:57,+0530,97334517,allstarcharts,J.C. Parets,,you guys see this Gilead? $GILD could see monster breakout if we take out the downtrend line from Q4 highs. I'd buy it on that confirmation,en,[],[],[],3,2,11,[],['gild'],https://twitter.com/allstarcharts/status/586561263355822080,False,,0,,,,,,,,[],,,,
582623228151074816,582623228151074816,2015-03-31 00:49:36 IST,2015-03-31,00:49:36,+0530,19546277,yahoofinance,Yahoo Finance,,Why Gilead stock could rise  http://t.co/ufzKjUdhZB via @OphirGottlieb $GILD,en,"[{'screen_name': 'ophirgottlieb', 'name': 'ophir gottlieb', 'id': '100024370'}]",['http://ophirgottlieb.tumblr.com/post/115049684049/why-gilead-stock-could-rise'],[],1,8,11,[],['gild'],https://twitter.com/YahooFinance/status/582623228151074816,False,,0,,,,,,,,[],,,,
580022440807538689,580022440807538689,2015-03-23 20:35:00 IST,2015-03-23,20:35:00,+0530,13171622,pharmalot,pharmalot,,Gilead warning of Hep C patient death on heart med will have 'zero impact' .. why? ..read here  http://t.co/U892GLgGSG #pharma $GILD $ABBV,en,[],['http://blogs.wsj.com/pharmalot/2015/03/23/gilead-warning-of-hep-c-patient-death-on-heart-med-will-have-zero-impact/'],[],0,12,6,['pharma'],"['gild', 'abbv']",https://twitter.com/pharmalot/status/580022440807538689,False,,0,,,,,,,,[],,,,
579985192242282496,579985192242282496,2015-03-23 18:07:00 IST,2015-03-23,18:07:00,+0530,466333756,seeitmarket,See It Market,,"New Post - ""Why Gilead Sciences Stock May Still Take Biotech Higher?""  http://t.co/cexbudzsjv by @MikeZaccardi $GILD $IBB $XLV $SPY",en,"[{'screen_name': 'mikezaccardi', 'name': 'mike zaccardi, cfa, cmt', 'id': '22073146'}]",['http://www.seeitmarket.com/will-gilead-sciences-stock-gild-take-biotech-higher-14207/'],[],0,2,5,[],"['gild', 'ibb', 'xlv', 'spy']",https://twitter.com/seeitmarket/status/579985192242282496,False,,0,,,,,,,,[],,,,
568093597943226368,568093597943226368,2015-02-18 22:34:03 IST,2015-02-18,22:34:03,+0530,18294275,fiercepharma,FiercePharma,,Crown the new drug launch king: Gilead's Harvoni has knocked aside sister med Sovaldi  http://t.co/FtaRGxpRbI $GILD #pharma #marketing,en,[],['http://www.fiercepharmamarketing.com/story/crown-new-drug-launch-king-gileads-harvoni-has-knocked-aside-sister-med-sov/2015-02-18'],[],0,8,6,"['pharma', 'marketing']",['gild'],https://twitter.com/FiercePharma/status/568093597943226368,False,,0,,,,,,,,[],,,,
567688025446969346,567688025446969346,2015-02-17 19:42:27 IST,2015-02-17,19:42:27,+0530,545618159,wrigleytom,Tom Wrigley,,Insider Buying at Gilead Sciences $GILD $ZIOP $YHOO   http://t.co/fJIPimXPAt,en,[],['http://247wallst.com/investing/2015/02/14/insider-buying-stays-solid-as-market-races-toward-record-highs/'],[],1,2,8,[],"['gild', 'ziop', 'yhoo']",https://twitter.com/WrigleyTom/status/567688025446969346,False,,0,,,,,,,,[],,,,
562887625267478529,562887625267478529,2015-02-04 13:47:22 IST,2015-02-04,13:47:22,+0530,449681624,h3nphlo,H3NPHLO,,Citi on Gilead's Q4 $GILD #HCV  http://t.co/x6g2TR6QAY,en,[],[],['https://pbs.twimg.com/media/B8_HT8VIYAAFb5X.png'],2,3,7,['hcv'],['gild'],https://twitter.com/H3NPHLO/status/562887625267478529,False,,1,https://pbs.twimg.com/media/B8_HT8VIYAAFb5X.png,,,,,,,[],,,,
562733812179017728,562733812179017728,2015-02-04 03:36:10 IST,2015-02-04,03:36:10,+0530,15563814,loftus,Peter Loftus,,"One-year haul for Gilead's sofosbuvir-containing HepC drugs (Sovaldi, Harvoni): $12.4B. Price Gilead paid for Pharmasset: $11B $GILD",en,[],[],[],1,21,10,[],['gild'],https://twitter.com/Loftus/status/562733812179017728,False,,0,,,,,,,,[],,,,
562672465277890560,562672465277890560,2015-02-03 23:32:24 IST,2015-02-03,23:32:24,+0530,624413,marketwatch,MarketWatch,,"Thanks to its $1,000-a-day hit hepatitis C drug, Gilead's Q4 net margin could exceed the 50% mark:  http://t.co/oHpUIVgqTi $GILD",en,[],['http://on.mktw.net/1LICS0S'],[],1,10,9,[],['gild'],https://twitter.com/MarketWatch/status/562672465277890560,False,,0,,,,,,,,[],,,,
548456243975553024,548456243975553024,2014-12-26 18:02:13 IST,2014-12-26,18:02:13,+0530,818081647,analystwire,SIAnalystWire,,"Gilead $GILD Could Unleash Massive Accelerated Repurchase, Suggests RBC Capital  http://t.co/MkafhX6urv",en,[],['http://streetinsider.com/r/10122934'],[],0,4,6,[],['gild'],https://twitter.com/AnalystWire/status/548456243975553024,False,,0,,,,,,,,[],,,,
